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ABSTRACT 
 
 
 
Structural Determination of Triclosan Derivatives as Inhibitors of Plasmodium 
falciparum Enoyl Reductase (PfENR). (December 2005) 
Edinson Lucumi Moreno, B.S., Universidad Del Valle (Colombia); 
M.S., Universidad de Barcelona (Spain) 
Chair of Advisory Committee: Dr. James C. Sacchettini 
 
 
 
Malaria is a disease that causes more than 1 million deaths per year world wide 
and more than 400 million clinical cases. Due to the acquired resistance of Plasmodium 
falciparum to the drugs used to control the infection, searching for new anti-malaria 
drugs is necessary in modern days. Recent studies have shown that the parasite 
synthesizes fatty acids using a fatty acid synthase type II (FAS-II) instead of a type-I fatty 
acid synthase (FAS-I) that is present in other eukaryotes. Plasmodium falciparum enoyl 
reductase (PfENR) is responsible for the last step of fatty acid biosynthesis in the 
parasite. This enzyme is located within the apicoplast, a plastid-like organelle that is 
responsible for several important metabolic pathways, including fatty acid biosynthesis. It 
is known that triclosan is an inhibitor of ENR in bacteria and we and others have shown 
that it is also effective against ENR in apicomplexan organisms such as P. falciparum. 
However triclosan cannot be used to treat malaria in humans because it has metabolic 
liability (glucoronidation) which limits its inhibitory potency. We have used X-ray 
 iv
crystallography and a Structural Activity Relationship (SAR) strategy to design and co-
crystallize a tertiary complex of PfENR with NAD+ and triclosan derivatives to improve 
their properties as drugs to treat malaria. More than five hundred triclosan derivatives 
were synthesized, and their in vitro and in vivo inhibitory activity evaluated. Furthermore, 
structural studies were made of their affinity to interact with residues in PfENR active 
sites, as well as with the cofactor NAD+. A total of six PfENR-NAD+-triclosan 
analog/complexes structures were determined. Analogs which had replacements of 
chloride groups at position 5 of ring A and 4’ of ring B were determined, allowing the 
structural analysis of the binding of these triclosan analogs to PfENR. In addition, the 
urea derivatives (modification at position 1) as well as phenylsulphonamides 
(modification at position 2’) have shown to be more potent inhibitors than triclosan in the 
in vivo assay. The analysis of the inhibitory properties and the structure of these analogs 
bound to PfENR will provide novel compounds in the search for new anti-malarial drugs. 
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CHAPTER I 
INTRODUCTION 
 
 
 
1.1. General Description about Malaria 
 Malaria is a parasitic disease transmitted by infected mosquitos of the genus 
Anopheles, and caused by parasites of the genus Plasmodium. It is an illness that has been 
part of human society since ancient times. For instance, it was common in the boggy 
realm surrounding the city of Rome in the times of the Roman Empire, acquiring its name 
from the Latin (mal-aria) that means “bad-air”; it was also known as the Roman fever. 1 
 Even though malaria originated in Africa, it is nowadays a worldwide problem. 
Malaria is common in all tropical regions in the globe. This means that it affects many 
communities in the poorest countries of the developing world. For instance, in south 
Saharan countries, malaria in addition to HIV are generating an epidemic (there is a death 
from malaria worldwide every 30 seconds) that has plunged Africa in a health and 
economic crisis, because the fact that these countries are losing high percentage of their 
young population. 1,2,3 
The fight against malaria has led the scientific community worldwide to approach 
its control from different directions. For example, many scientists in different institutions 
and some pharmaceutical companies are researching the development of an effective 
vaccine against the parasite. However, due to the complexity of this disease, the degree of 
protection offered by these vaccines have shown to be very limited.3 
This thesis follows the format of the Journal of Medicinal Chemistry. 
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Another strategy has been to focus on controlling the vector (mosquito of the 
genus Anopheles) responsible of malaria transmission: First, by creating physical barriers 
in the house such as bed nets impregnated with insecticide (pyrethroid emulsion) to avoid 
bites from the mosquito. Second, by spraying the inside of the walls and roof of the 
houses with a residual insecticide, and Third by controlling breeding water places were 
development of the larva mosquito take place. Even though people located in rural 
regions of countries where malaria is a health problem follow these methods to prevent 
the disease, high percentage of the population still get infected.4 
The control of malaria using antimalarial drugs has mainly been focused in the 
use of quinine, an alkaloid found in the bark of plants of the genus Cinchona (used for 
more than three centuries, but now used only in severe falciparum malaria by reason of 
its side effects) and its derivatives chloroquine, mefloquine and more recently 
sulphadoxine-pyrimethamine. Chloroquine has been used since the 1940’s, it has scant 
side effects and low cost, making possible its use by many rural communities in 
developing countries. Other drugs that have been used in the treatment of malaria are: 
Atebrin, proguanil, malarone, maloprim, fansidar, halofantrin, and artemisinin. However, 
these drugs have induced the emergence of new resistant strains of Plasmodium. 
Therefore, malaria control is day by day a more difficult challenge for the scientist 
researching this disease.1,2,4,5 
As part of this fight against malaria, the determination of the genome sequence of 
P. falciparum generated the possibility to identify critical enzymes (drug targets) 
involved in various metabolic pathways within the parasite’s metabolism. One of these 
new enzymes is the P. falciparum enoyl reductase (PfENR) which is involved in the last 
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step of fatty acid biosynthesis, a pathway essential for the survival of apicomplexan 
parasites.5,6,7,8 
PfENR is located within the apicoplast, a recently discovered organelle in P. 
falciparum that has a bacterial origin, where several metabolic processes take place. The 
parasite uses for the biosynthesis of fatty acids a so called type II fatty acid biosynthetic 
pathway, in which several enzymes are responsible for different steps in the biosynthesis 
of these essential metabolites. This differs from type I fatty acid biosynthesis that takes 
place in other eukaryotic organisms, where one multi-functional enzyme complex is 
responsible for the process.8, 9, 10 
One of the inhibitors of bacterial ENR is 5-chloro-2-(2,4-dichlorophenoxy) 
phenol (triclosan).11 This is used as an antibacterial in hospital hygiene and cleaning 
products, among other applications.11,12,13 Surolia and Surolia in 2001 found that triclosan 
inhibits P. falciparum ENR, making possible its evaluation as a potential inhibitor of this 
enzyme and its study as a potential candidate for the treatment of malaria.14 However, the 
phenol group of triclosan has a metabolic liability (glucuronidation) making it susceptible 
to modification in human metabolism.10,15,16 Our research has focused on the synthesis, in 
vivo (whole cell) and in vitro (enzyme) inhibitory evaluation, and structural elucidation of 
triclosan derivatives less prone to modifications that could act as inhibitors responsible of 
increasing the inhibitory potency of these new types of possible anti malarial drugs. The 
development of this project has been a joint effort among private industry (Jacobus 
Pharmaceutical Company) and several Universities (Department of Microbiology and 
Immunology at Albert Einstein College of Medicine, and the Department of 
Biochemistry and Biophysics at Texas A&M University). 
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1.2. Malaria Transmission 
The United Nations tried to eradicate malaria in the early 50’s by reducing 
infecting vectors population feeding on humans, as well as making malaria prophylactic 
drugs available to anyone anywhere. However, in this century malaria still claims the 
lives of more than 2 million people per year and, there are 300-500 million clinical cases 
every year.2,4,5,17 
Malaria is transmitted by the bite of the female Anopheles mosquitoes that has 
bitten an infected host (human).18 The vector is carrying the sporozoites stage of the 
parasite (Scheme 1) which enters the bloodstream and localizes in the liver of the infected 
human. The division of these sporozoites produces the merozoites which are the stage of 
the parasite that infects red blood cells. These merozoites differentiate into special cells 
called gametocytes that are ingested by the mosquito. These cells then combine in the gut 
with other gametes (sperm and egg) to form a zygote that, in turn, after division, gives 
rise to the sporozoites which then migrate to the mosquito salivary glands to start the 
cycle over again (Scheme 1).13,19,20  
After transmission, clinical manifestation of malaria depends upon immune state 
of the host and the degree of parasitemia. Children with no immunity endure serious 
manifestations while those with immunity have fewer symptoms regardless of massive 
parasitemia. There is more mortality of children under the age of 5 years than in adults 
due to malaria. The incubation period for Plasmodium vivax is 10-18 days, 11-16 days for 
P.ovale and P.malariae and 7-14 days for P.falciparum. 20 
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Symptoms related with malaria infection are: Headache, nausea, general weakness, body 
ache, loss of appetite, and vomiting. Fever is one of the main symptoms of malaria; it is 
described as convulsive high fever with chills. Malaria produced by P.falciparum 
frequently renders with consecutive fever complications, which include cerebral malaria 
related with convulsion, delirium, altered consciousness and deep coma.20 
 
 
 
 
Scheme 1 Life Cycle of P. falciparum 
Sporozoites enter the bloodstream of the infected host and then localize in the liver, 
where they divide and produce the merozoites that goes to infest the erythrocytes, 
gametocytes are produced from these merozoites to further be ingested by the mosquito 
and by combination with the other gametes form a zygote from which sporozoites are 
produced to allow the cycle to continue6. 
 
 6
 
1.3. The Vector Mosquito (Anopheles gambiae) 
“There are around 3200 species of mosquitoes belonging to 42 genera, and only 
one genus, Anopheles, is able to transmit human malaria. The genus Anopheles contains 
around 430 known species of which approximately 70 are malaria vectors, but only 40 of 
these are thought to be of any major importance. Anopheles mosquitoes have an almost 
world wide distribution, although they typically are not found at altitudes above 2500m. 
During growth and metamorphosis, the mosquito passes through four distinct stages: egg, 
larva, pupa and adult. The immature stages are aquatic, depending on free water for their 
survival and development.18 
The genus is divided into six subgenera, four of which include disease vectors. 
Among the species of Anopheles is A. gambiae that predominates in humid areas, prefers 
feeding on humans resting indoors being a highly efficient malaria vector. A. arabiensis 
is found in savannah regions, readily bites humans, may rest indoors, often feeds on cattle 
and rats, and is the second most important vector in malaria transmission. Other species 
include A. quadriannulatus, A melas, A.merus, and A. bwanmbae”.18 
 
1.4. The Parasite (P. falciparum) 
“Protozoa of the genus Plasmodium are responsible of causing malaria. The 120 
or so species of Plasmodium are found in the blood of mammals, reptiles and birds, and 
are recognized taxonomically by the presence of two types of asexual division: 
schizogony, in the vertebrate host; and sporogony, in the insect vector. Within the 
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vertebrate host schizogony is found within erythrocytes (erythrocytic schizogony).18 Two 
subgenera of the parasites are found in humans, Laverania and Plasmodium. The 
subgenera Plasmodium include the most pathogenic form of malaria Plasmodium 
falciparum, and the closely related P. reichenowi.18 The subgenera Laverania include the 
remaining parasites of humans, namely P.vivax, P.malarie and P. ovale. Three malaria 
parasites are found exclusively in humans: P. falcuparum, P. vivax and P. ovale.”18 
 
1.5. The Apicoplast 
The apicoplast is an organelle similar to plastids in plants that contains a 35 kb 
circular genome that encodes components of a prokaryotic transcriptional and translation 
system. The apicoplast is surrounded by four membranes and contains its own genome, 
this being a characteristic cellular feature of apicomplexan parasites.8,9 
Apicoplast functions include fatty acid and isoprenoid synthesis. Studies of plastid 
inhibitors and apicoplast mis-segregation mutants confirmed the essential requirement of 
this organelle for normal parasite development, indicating that inhibition or loss of 
apicoplast function resulted in parasite death accompany by reinvasion of host cells.  
The apicoplast localization of de novo fatty acid biosynthetic enzymes renders, by 
analogy with the plant plastid, the first argument for the endosymbiosis (algal cell which 
had previously incorporated a cyanobacterium) origin of the pathway.14,21,26 
The multi-subunit type II fatty acid synthase (FAS II) found in bacteria and plant 
plastids is also present in the apicoplast of Plasmodium and Toxoplasma. Proteins 
involved in these pathways are often the products of nuclear genes that encode N-terminal 
signal and transit peptide sequences for apicoplast localization. On the other hand the fas 
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I gene, which encodes a multi-domain protein, the FAS I enzyme, found in the cytosol of 
animal cells has not been found in apicomplexan genomes. 8-11,22-26 
 
1.6. Fatty Acid Biosynthesis 
Fatty acids are important metabolites for supplying precursors to make part of 
biological membranes as well as an essential mode of storage metabolic energy. 
Therefore, biosynthesis of fatty acids is a common process in biological systems. 10,11,21,25  
One of the most complex multifunctional polypeptide structures in animals is the 
fatty acid synthase. It is a single polypeptide that contains all the catalytic components 
responsible for the reactions that lead to the formation of, for example, palmitic acid from 
acetyl-CoA and malonyl-CoA. Formation of these products involve seven enzymatic 
reactions that were first studied in E.coli (where the reactions are catalyzed by 
independent enzymes) 25-32 
In some mycobacteria, higher eukaryotes, and yeast the biosynthetic enzymes are 
embodied into a large multifunctional polypeptide in which different reactions in the 
pathway are catalyzed by different domains of this elaborated enzyme. It is commonly 
referred to as type I fatty acid synthase (FAS-I), and the pathway is also called associated 
pathway. The fatty acid synthase found in yeast is a 2500 kDa α6 β6 multifunctional 
enzyme, while in animals α2 is a 534 kDa multifunctional enzyme consisting of two very 
similar polypeptides chains.10,21,25-32 
The fatty acid biosynthesis pathway is a cyclic process in which an acetyl primer 
originally linked as a thioester in acetyl-CoA experiences a series of decarboxylative 
condensations with seven malonyl moieties. Each condensation reaction generates a 3-
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ketoacyl moiety that goes through the same three-step β-carbon reduction to create an 
entirely saturated acyl moiety two carbons longer than that in the previews cycle. Thus, 
after conclusion of seven cycles of elongation and reduction, the final product is the 
saturated C16 fatty acid, palmitic acid.10,27 
A dissociated pathway mainly found in bacteria, plants (chloroplast), algae 
plastids and recently discovered in apicoplexan parasites (P. falciparum) is responsible 
for fatty acid biosynthesis in steps performed by separate distinct enzymes. This pathway 
is referred to as fatty acid synthase II (FAS-II) system. The enzymes involved in this type 
II FAS in E.coli are:  
ACP transacylase (FabD) responsible of producing malonyl-ACP from malonyl 
CoA and ACP, β-ketoacyl-ACP synthase III (FabH) that catalyzes the condensation of 
malonyl-ACP and acyl CoA (acetyl-CoA) forming a β-ketoacyl-ACP product, β-
ketoacyl-ACP reductase (FabG) which reduces the β-ketoacyl-ACP to β-hydroxyacyl-
ACP by the sequential action of β-hydroxyacyl-ACP dehydrase (FabA or FabZ) and 
enoyl-ACP reductase (FabI). 
In E. coli ACP is a 10 kDa polypeptide and the elongation cycle to produce the β-
ketoacyl-ACP product is catalyzed by two enzymes: acyl-malonyl-ACP (β-ketoacyl-ACP 
synthase I (FabB)) or β-ketoacyl-ACP synthase II (FabF) depending on the chain length 
of the acyl-ACP substrate. The product of FabF or FabB is then exposed to another round 
of reduction catalyzed by FabG, FabZ and FabI. In each cycle that the elongation takes 
place the acyl-ACP product is amplified by two carbons (Scheme 2). 10,11,21,26,33 
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The general reaction for the conversion of the substrate crotonoyl CoA to butyryl 
CoA is shown in Scheme 3. ENR is the enzyme responsible of completing cycles of fatty 
acid elongation in vivo. ACP thioesters are utilized by the enzymes of fatty acid 
biosynthesis.34,35 The enzymes responsible of fatty acid biosynthesis in P. falciparum are: 
Acetyl –CoA Carboxylase 
The source of corbon units in FAS II system is derived from acetyl-CoA. In P. 
falciparum a pyruvate dehydrogenase complex is the source of acetyl CoA for fatty acid 
biosynthesis and it is localized within the apicoplast. In addition, acetyl CoA carboxylase 
(ACCase) form malonyl-CoA from acetyl CoA and bicarbonate that is required for FAS 
II. Interestingly, ACCase from P. falciparum is similar to a multi-domain ACCase found 
in the cytosol of plants. The maturation of P. falciparum in red blood cells can be reduced 
likely toward the inhibition of ACCase by the action of inhibitors like 
aryloxyphenoxypropionate (fops and dims) herbicides with IC50 values of 100-200 
µM.21,36-43 
 
Acyl Carrier Protein 
One of the fundamental enzymes involve in type II FAS is acyl carrier protein 
(ACP). The acyl intermediates are covalently attached to ACP through a thioester linkage 
in every phase of the pathway. PfACP is a protein of 137 amino acids encoded by the 
pfacp gene located in chromosome 2. This enzyme is thought to target the apicoplast. 
Participation of ACP in fatty acid biosynthesis depends on the addition of 4’-
phosphopantetheine prosthetic group to ACP, which is responsible for the attachment of 
the acyl groups during fatty acid biosynthesis. The transfer of this prosthetic group from 
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coenzyme A to a conserved serine found in all ACP proteins is made by holo–ACP 
synthase (in E.coli it is called EcAcpS). On the other hand, the P. falciparaum ACP 
synthase enzyme is 29% identical to EcAcpS and it is called PfAcpS, it may target the 
apicoplast. However this enzyme remains to be studied to open the possibility to be a 
good target for antimalarial drugs evaluation.21,44-46 
 
Malonyl-CoA ACP Transferase 
The first step to start the chain elongation in type II FAS is catalyzed by malonyl-
CoA: ACP transacylase (MCAT), this enzyme is found in P. falciparum (PfMCAT). It is 
thought that this enzyme targets the apicoplast. However, there is a lack of relevant 
studies to confirm this. The catalytic domain of PfMCAT shares 28% sequence identity 
with EcFabD. Even though its crystal structure is not defined yet, it is hypothesized to 
expose an overall fold similar to that seen in the structure of its similar found in E. coli 
homolog. The active side residues are well conserved in PfMCAT and MCATs from 
different organisms.47-49 
There have been several mutagenesis studies that revealed some non catalytic 
residues in the active side of MCAT and present in PfMCAT that are involved in 
maintaining the turnover rate of this enzyme, conferring substrate specificity for malonyl-
CoA. Knowing these, structural and mechanistic characteristics of this enzyme together 
with rational design of inhibitors that target this enzyme can be accomplished, because 
MCATs and, particularly PfMCAT can be an interesting target to explore antimalarial 
drugs development, due to the essentiality of this enzyme for the survival of the 
parasite.49-51 
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β-Ketoacyl–ACP Synthase III 
This enzyme catalyzes the second step of chain initiation and elongation in type II 
FAS, and the gene that encodes this enzyme (pfkasIII) was one of the first to be identified 
in P. falciparum genome project, indicating the presence of FAS II system in this 
organism. The enzyme responsible for this function in E. coli is EcFabH, its catalytic 
domain shares 35 % identity with PfKASIII being C-H and N common residues in these 
proteins active side. Some studies also have shown that PfKASIII catalyzes two reaction: 
acyl CoA:ACP trans acylase (ACAT) activity and β-ketoacyl-ACP synthase (KAS) 
activity useful for the implementation of PfKASIII inhibitory screen assay.52-54 
Due to the particular function of this enzyme as a condensation enzyme there 
have been significant efforts to find inhibitors of this enzyme as antibacterial agents. For 
example, the use of cerulenin an inhibitor of KAS in type I and II FAS, being this 
disadvantageous to be used in humans. On the other hand, thiolactomycin inhibits P. 
falciparum, probably by binding to other condensing enzymes PfKASI/II also found in P. 
falciparum but not being characterized yet. Currently, thiolactomycin derivatives as well 
as indole analogs are the main scaffold used in high throughput screening for the design 
of drugs that target PfKASIII.21,55-57 
 
β-Ketoacyl–ACP Reductase 
This enzyme (PfKAR) catalyzes the NADPH dependent reduction of β-ketoacyl–
ACP to β-hydroxyacyl–ACP product. There are no studies demonstrating the apicoplast 
localization of this protein (PfKAR). This enzyme belongs to the short-chain 
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dehydrogenase/reductase (SDR) family of enzymes, sharing 47% sequence identity with 
E. coli FabG (EcFabG) and has the typical catalytic triad motif S-Y-K. Additionally, 
KAR is found as a single isozyme in bacteria making it an ideal antibacterial drug target. 
However there are no reports of specific inhibitors of KAR in P. falciparum.21,58-64 
 
β-Hydroxyacyl–ACP Dehydratase 
This enzyme (PfHAD) is responsible of the dehydration of β-Hydroxyacyl–ACP 
to trans-2-acyl-ACP. The localization of this enzyme into the apicoplast is still a matter 
of study. However, it seems likely that 76 amino acids in the amino-terminal region 
comprise an apicoplast leader peptide, in addition to a 154 amino acid enzymatic domain 
that shares 21% identity with EcFabA and 42% sequence identity with EcFabZ. These 
two enzymes catalyze the dehydration of β-hydroxyacyl-ACP in E. coli, and EcFabA also 
catalyzes the isomerization of trans-2-acyl-ACP to cis-3-acyl-ACP. The determination of 
the crystal structure of EcFabA has been done with and without inhibitor bound to the 
enzyme, allowing the determination of an aspartic acid residue in the active side 
(glutamate in EcFabZ) that is likely to be important for the additional trans/cis isomerase 
activity of EcFabA. PfHAD lacks the presence of the aspartic acid residue; however, it 
has the glutamate present in EcFabZ, and considering its high sequence identity this 
indicates that PfHAD does not have isomerase activity and that it is a monofunctional 
dehydratase.65-68 
PfHAD is currently the subject of inhibition studies. More than 400 compounds 
have been tested and their inhibitory activities have been shown to be less than 1µM and 
the IC50 for P. falciparum around 100µM for some specific compounds. The structure of 
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PfHAD awaits to be determined and it will offer a clearer understanding of the design of 
more potent inhibitors that target this important enzyme in P. falciparum fatty acid 
biosynthesis.21,69 
 
Enoyl-ACP Reductase 
One of the most important enzymes in the FAS II system and responsible for the 
last step in the pathway, is enoyl-ACP reductase (ENR). This enzyme is responsible of 
the limiting step (conversion of trans-2-acyl-ACP to acyl-ACP) in fatty acid chain 
elongation cycle. In P. falciparum apicoplast localization of this enzyme still has to be 
determined, however there is a 77 amino acid sequence in the N-terminal region of 
PfENR that appears to target the apicoplasst. PfENR shares 16% sequence identity with 
E. coli FabI, 47 % with its similar in the plant Brassica napus. Its homolog in M. 
tuberculosis is called InhA. Several studies have shown that PfENR uses NADH as a 
cofactor for the catalytic reaction in which crotonoyl-CoA is transformed into the product 
butyryl-CoA, being the detection of the depletion of NADH to NAD+ followed at 340nm. 
11,70-72 
Recently, PfENR is the subject of the search for different types of inhibitors that 
target this enzyme. However, these studies are based on the previous knowledge of 
several bacterial ENR inhibitors such as diazaborine, isoniazid, ethionamide and 
triclosan, being this last one very effective inhibitor of PfENR. In addition, several 
studies report the x-ray crystal structure of PfENR-NAD+-triclosan tertiary complex, 
conferring structural information of triclosan mode of inhibition. However, use of 
triclosan in malaria medical treatment is restrained by its metabolic liability.21,73,74 
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Scheme 2 Enzymes of Fatty Acid Elongation  
Reactions in fatty acid biosynthesis are initiated by β-ketoacyl-ACP synthase III, which 
condense malonyl ACP with acetyl-CoA, followed by a reduction of the β-ketoester by β-
ketoacyl-ACP reductase. β-hydroxyacyl-ACP dehydrase catalyzes the elimination 
reaction and the final conversion of trans-2-enoyl-ACP to acyl-ACP is catalyzed by the 
single NADH-dependent enoyl-ACP reductase (FabI) starting the elongation cycle over 
again11. 
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Scheme 3 Reaction Catalyze by ENR 
Reduction of crotonoyl-CoA into butyryl-CoA, wherein NADH acts as the coenzyme 
catalyzed by ENR16 
 
1.7. Plasmodium falciparum Enoyl Reductase (PfENR) 
The parasite responsible of producing malaria in humans (Plasmodium 
falciparum) synthesizes fatty acids using a type II pathway that is absent in humans. The 
enoyl reductase gene in this organism (pfenr) encodes an anticipated protein of 
432 amino acids with an expected molecular weight of 49.8 kDa, enoyl acyl carrier 
protein reductase or Plasmodium falciparum enoyl reductase (Figure 1 and 2). 10,11 
PfENR is a tetramer, and is responsible for the final step in fatty acid elongation. 
This enzyme targets the apicoplast and is a validated antimicrobial drug target.11 PfENR 
shows 47% sequence similarity to enoyl reductases from Brassica napus as is illustrated 
in Figure 1. The PfENR sequence differs from those other ENRs in that it contains a 43 
amino-acid insert in a loop which in the ENRs from other species is known to experience 
appreciable conformational change on inhibitor (and likely substrate) binding (Figure 2) 
This enzyme also has a particular low complexity region between residues 325-367 
(underline red region in Figure 1) enriched in polar residues like asparagines, lysine 
glutamine and serine. Even though it has been found that this insertion have been 
reported in other P. falciparum enzymes, they have minimal impact on the enzyme 
functionality11  
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As it is described in Figure 2 each subunit of PfENR is composed of seven β-
strands (β1- β7) that form a parallel β-sheet and nine α helices (α1 – α9) that are 
connected to the β-strands by a number of loops of varying length. The parallel β-sheet is 
bordered by helices α1, α2, α4, α5, α6, and α9, with α3 arranged along the top of α2 and 
α4. Helix α8 is located at the C termini of strands β6 and β7. The loop regions between 
α2- β3, β3 - α3- α4, and β4 - α5 of PfENR are longer due to insertions in the sequence, 
and helix α2 was shifted away from the protein, toward the solvent, relative to the 
bacterial ENRs.11 (Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 1.Aminoacid Sequence of PfENR. 
Sequence alignment representation of PfENR aligned with sequences of homologues 
ENR’s from Plasmodiun bergei (pbENR), Plasmodium vivax (pvenr) Brassica napus 
(bnapus), Escherichia coli (ecoli), and Mycobacterium tuberculosis (mtb). Green 
(complete conserved residues) yellow (two or more highly conserved residues) grey (at 
least one similar amino acid residue), the catalytic important residues are marked by (*) 
and the low complexity region by the red line.11 
 
* *
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Figure 2.Structure of PfENR. 
Representation of PfENR monomer with NADH bound at the active site, it is composed 
of seven β-strands and nine α helices. 
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1.8. Triclosan  
5-chloro-2-(2’,4’-dichlorophenoxy) phenol (triclosan) (Figure 3 ) is a chemical 
that has been used since the 60’s as an antibacterial and an antifungal agent, it was 
invented by Ciba more than 40 years ago. Since then, it has been incorporated in many 
common use products for humans such as, soaps, toothpastes, cosmetics, toys etc.75 It is 
suggested that triclosan blocks lipid biosynthesis by specifically inhibiting the fabI gene 
product of E. coli, the InhA product of M. smegmatis, and the enzyme enoyl-acyl carrier 
protein reductase (ENR) by mimicking its natural substrate.12 E. coli enoyl reductase is 
also known to be inhibited by the antibacterial diazaborines, and the enoyl reductase of 
mycobacterium is a target of the antitubercular drug isoniazid.76-90,91 
 
 
 
 
 
 
 
 
 
Figure 3.Structure of Triclosan. 
Structure of triclosan specifying the location of each possible substitution in the 
molecule, the hydroxyl group (red) at ring A, the chloride groups at position 2’,4’ and 5 
(green) as well as the ether group at the linker position (red) 
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There have been limited studies of triclosan metabolism. As a hydroxylated 
compound, it should be expected that glucoronidation and sulfonation would be the main 
pathways of triclosan metabolism.10,77 One study showed that triclosan was excreted 
primarily as the glucuronide following application of a 1% formulation to guinea pig or 
rat skin. Another study showed that topically applied triclosan formed sulfate and 
glucuronide conjugates in human as well as rat skin.10,77,80-86, The human hepatic 
biotransformation of triclosan has not been reported in the open literature. There have 
been no studies of the possible interactions of triclosan with Type II fatty acid 
biosynthesis enzymes.77 Wang et al77 reported that triclosan was metabolized to 
glucuronide or sulfate conjugates in the presence of human liver microsomes or cytosol, 
respectively. Exposure to concentrations of triclosan higher than 20 µM should have 
resulted in glucuronidation being the predominant pathway in the liver.77,82,83 
On the other hand, several studies report triclosan resistance in E.coli, being this 
the same point mutation (A217V) that affects the affinity of triclosan to PfENR. In 
addition, triclosan presents poor bioavailability indicating a potential limitation in the use 
of this compound in the field. Recent research suggested the use of arginine oligomers to 
overcome this problem. In this study triclosan was attached to octaarginine via a 
hydrolisable ester linkage, proving that triclosan modified in this manner has in vitro 
therapeutic activity. 10, 78,79,91 
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1.9. Dose Response Curves of Enzyme Inhibition 
Biological assays are defined as tools to determine a property of a specific system 
of study. It is done by measuring a specific signal as a function of the concentration of 
some exogenous compound The results of these types of measurements are presented as 
plots of the signal obtained as a function of the concentration of the exogenous substance. 
These graphs are referred as a dose response plots; the representation of the change in 
signal with change in concentration of substance is known as a dose response curve. 
The resulting plots have the form of a Langmuir isotherm; they can be used to follow 
protein-ligand binding equilibrium to further track the inhibitory effect of a particular 
compound on the initial velocity of an enzymatic reaction at an adjusted concentration of 
substrate.87 
The IC50 value is defined as the concentration of inhibitor essential to achieve a 
half-maximal level of inhibition. Thus the equation that represents the effect of the 
inhibitor concentration on the velocity of the reaction is associated to the Langmuir 
Isotherm equation as follow: 
 
Equation 1 
 
 
Where: 
Vi is defined as the initial velocity in the presence of inhibitor at concentration [I] 
Vo is defined as the initial velocity in the absence of inhibitor 
+
[I] 
IC50   
 
1
=
1Vi 
V0
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Vi/Vo is defined as the fractional net effect of the inhibitor on enzyme activity. 
The real term to define the effectiveness of a compound is the dissociation 
constant of that compound for the enzyme. However, Vi/Vo gives an acceptable 
estimation of the inhibitory activity of the compound being studied.87 
Changes in solution conditions have an effect in the IC50 value of a particular inhibitor. 
As a result, when we compare different types of competitive inhibitors, it has to be taken 
into account that the IC50 values must be measured at the same concentration of substrate, 
there will be different variation in IC50 values of a non competitive and a competitive 
inhibitor when we vary the substrate concentration. 
Accordingly, the effectiveness observed in vitro under a particular set of solution 
conditions may not be the same effectiveness observed in vivo, where the conditions are 
different. It is more acceptable to use the Ki values to compare the inhibitory potency of 
different compounds. 87 
By derivation of velocity equations we can determine the relationship between Ki, [S], 
Km and IC50 for competitive, non competitive and uncompetitive inhibitors, giving as a 
result equations 2 and 3  
For noncompetitive inhibitors: 
 
Equation 2 
 
 
If α = 1 then Ki = IC50 
 
 
IC50  = 
[S]  +  Km 
[S] 
αKi
Km 
Ki +
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For uncompetitive inhibitors: 
 
Equation 3 
 
If [S] >> Km, then α Ki ~ IC50 
 
The IC50 values can be converted to Ki values using the above equations, however we 
must know the mode of inhibition of the compound being analyzed. 
A common strategy used in developing structure-activity relationships is to 
determine important variations in the inhibitory mechanism shared by a series of related 
compounds, assuming that all the derivative molecules share the same mode of inhibition 
as the parent molecule. In this way, it can be determined the mode of inhibition for the 
parent molecule only, and then apply equations 2 and 3 to the rest of the type of 
molecules been studied 87 
 
 
 
 
 
 
 
 
IC50 
+
αKi = Km 
[S]  
 
1
 24
CHAPTER II 
EXPERIMENTAL SECTION 
 
 
 
2.1. Preliminary Studies 
After the discovery of triclosan as an inhibitor of ENR in P. falciparum by Surolia 
and Surolia,14 several studies have focused in the design of antimalarial drugs that target 
fatty acid biosynthesis. Perozzo et al.11, defined the structure of PfENR in a binary 
complex with NAD+ and as a tertiary complex with NAD+ and triclosan, giving insights 
to the mode of binding of triclosan to PfENR as well as the characteristics of the active 
site of the protein, allowing the design of different kinds of triclosan derivatives that 
could inhibit PfENR. 11,73,92 
Triclosan (Figure 3) binds forming a non covalent complex with NAD+(NADH) 
and with PfENR mainly forming hydrogen bonds. This mode of binding exhibit π-π 
stacking interaction between the nicotinamide ring of NAD+(NADH) and the phenol ring 
(A) of triclosan. This same ring formed additional van der Waals interactions with the 
side chains of Tyr267, Tyr277, Pro314, Phe368, and Ile369. In addition to hydrogen-
bonding with the 2'-hydroxyl group of the nicotinamide ribose and with Tyr277.11 
Studies on inhibitors of E. coli FabI reported the use of compound 4 (Figure 4)73 
In this study it was shown that this naphthyridinones display similar binding interactions 
with NAD+ and the active site of FabI to those found for triclosan; the linking amide 
carbonyl is positioned for an H-bond interaction with the 2'-hydroxyl of NAD+ and the 
hydroxyl of tyrosine156. The central cis-amide fragment of compound 4 (Figure 4) 
appears to participate in a π-π stacking interaction with the nicotinamide portion of 
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NAD+. Alanine95 is involved in H-bond interactions that bind both the pyridylamine and 
the N-acyl hydrogen of the naphthyridinone moiety.73  
InhA is the ACP in M. tuberculosis. It is inhibited by isonicotinc acyl-NADH 
compound 9 (Figure 4), an adduct molecule that is the product of the activation of 
isoniazid compound 8 (Figure 4) (a pro-drug that is activated in the active site of several 
ACPs in presence of KatG which catalyzes the oxidation of Mn+2 to Mn+3) and NADH, to 
form the adduct.76,88 This isonicotinic acyl-NADH binds to the active site of PfENR 
producing a conformational change in the residue Tyr267 whose side chain rotates ~30º 
and forms an aromatic ring-stacking interaction with the pyridine ring of the isonicotinic 
acyl group. The nitrogen of the isonicotinic acyl group, the oxygen of Tyr267 hydroxyl 
group and an ordered water molecule form a hydrogen-bonding network. The carbonyl 
oxygen of the isonicotinic acyl group, the 2’- hydroxyl oxygen of the nicotinamide ring, 
the oxygen of Tyr277 hydroxyl group and a highly ordered water molecule form another 
hydrogen-bonding network. (Wang et al. personal communication) 
Perozzo et al.11 reported two triclosan derivatives, compounds 6 and 7 (Figure 4), 
where modifications were made mainly on the linker, OH group and substituents in the A 
and B ring of the molecule. These substitutions did not increase the inhibitory activity of 
those inhibitors compared to triclosan. Therefore, more studies in the possible 
substituents that will increase triclosan derivatives affinity for the enzyme will be 
necessary. 
In this study, we have synthesized and evaluated in vivo and in vitro inhibitory 
activity of more than 500 triclosan derivatives as PfENR inhibitors, as well as co-
crystallized those that have an effective inhibition of the enzyme. The purpose of this is 
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to gain information for the design of more potent PfENR inhibitors where a gain in 
suppression of PfENR activity could facilitate substitution or removal of the phenol 
group in ring A of triclosan that is susceptible to metabolic liability (glucuronidation) in 
human metabolism producing clearance of triclosan.10 
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Figure 4. Structures of Known PfENR Inhibitors. 
Structures of different kind of PfENR inhibitors including triclosan (5) and triclosan 
analogs (6,7) 
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2.2. Synthesis of Triclosan Derivatives  
The synthesis of triclosan derivatives was accomplished by Jacobus 
Pharmaceutical Company. The synthesis strategy focused mainly on substituents at 
position 1, 5 of ring A and 2’ and 4’ on ring B, as well as some miscellaneous compounds 
(Figure 5). These analogs allow us to acquire information about the interaction among 
those particular substituents on triclosan with the amino acids located in the active site 
that might increase the binding capacity of those inhibitors, and therefore, their potential 
as possible drug candidates to treat malaria. 
2'-substituted triclosan derivatives were prepared via standard reductive amination 
protocols using NaBH(OAc)3 from the corresponding benzaldehyde and aminomethyl 
precursors. The benzaldehyde precursor was synthesized from 4-chloro-2-methoxyphenol 
and the appropriate o-fluorobenzaldehyde via nucleophilic aromatic substitution (SNAr) 
chemistry. The aminomethyl derivatives were afforded by a two step procedure: SNAr 
reaction of 4-chloro-2-methoxyphenol with the appropriate o-fluorobenzonitrile and then 
lithium aluminum hydride reduction of the nitrile. In the case of the α-α-dimethylated 
aminomethyl derivatives, reaction of the corresponding aryl nitrile with CeCl3/MeLi in 
tetrahydrofuran furnished the amine derivative (Figure 5). 
The synthesized 5-substituted triclosan derivatives were prepared via a range of 
synthetic strategies. Synthesis of the 5-aryl triclosan subclass began with a Suzuki 
reaction between 4-bromo-2-methoxyphenol and the appropriate arylboronic acid or 
boronate ester. This m-arylphenol was then reacted with the appropriate aryl fluoride in a 
nucleophilic aromatic substitution (SNAr) reaction. Cleavage of the remaining methoxy 
group was achieved by stirring with an excess of boron (III) bromide. The 5-alkyl and 5-
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alkylaryl subclasses were prepared from the corresponding 5-aldehyde triclosan 1-methyl 
ether intermediate (itself prepared via SNAr reaction of the necessary phenol and aryl 
fluoride pieces) via a three step protocol: reaction with the appropriate alkyl- or aryl-
Grignard reagent, ionic dehydroxylation of the benzylic alcohol with trifluoroacetic 
acid/triethylsilane, and methyl ether cleavage with boron (III) bromide (Figure 5). 
The urea derivatives were prepared using classical methods for urea synthesis. In 
some cases, the isocyanate was condensed with the appropriate amine precursor to afford 
the desired urea which was isolated via precipitation from the reaction mixture. 
Otherwise, a solution of one amine was stirred with phosgene or triphosgene in the 
presence of base to afford an intermediate isocyanate that was then condensed with the 
second amine to afford the urea product (Figure 5). 
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Figure 5. Structures of Possible Triclosan Analogs. 
Types of triclosan derivatives generated in this study by modification of position 1, 2’, 4’ 
and 5’ as well as modification in the linker ether atom and some miscellaneous 
compounds. 
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2.3. In Vivo Whole Cell Evaluation 
The inhibitory activities of triclosan and its analogs against P. falciparum asexual 
blood stages were performed by our collaborators at the department of Microbiology and 
Immunology at Albert Einstein College of Medicine. A 72-h in vitro assay that measures 
decreases in [3H] hypoxanthine uptake as a marker of growth inhibition was used. Two 
strains of P. falciparum were used in this study, strain 3D7 is chloroquinine sensitive and 
strain Dd2 that is chloroquinine resistant, and the values for this results are reported as 
two different measurements of IC50/IC90. 
 
2.4. PfENR Expression and Purification 
The expression and purification of PfENR was performed as is described by 
Perozzo et al.11 A BL21 (DE3) Codon+-RIL cells (Novagen) harboring the expression 
plasmids were grown in terrific broth. The cells were induced with 1 mM isopropyl-1-
thio-β-D-galactopyranoside when the optical density reached 1.6 (A600) for 5 hours at 
37 °C. Cell pellets were resuspended in lyses buffer (20  mM Tris/HCl, pH 8.0, 500  mM 
NaCl, 50  mM imidazole) and disrupted using a French press. The filtered supernatant 
was applied to a metal chelate (Pharmacia) affinity column loaded with nickel. The 
column was washed with buffer B (20  mM Tris/HCl, pH 8.0, 500  mM NaCl, 150  mM 
imidazole) and eluted with buffer C (20 mM Tris/HCl, pH 8.0, 500  mM NaCl, 400  mM 
imidazole). The protein was concentrated using Amicon ultra Millipore and applied to a 
 31
Superdex 200 size-exclusion column equilibrated with buffer D (20  mM Tris/HCl, pH 
7.5, 150  mM NaCl).11 
 
2.5. In Vitro PfENR Evaluation 
For the in vitro determination of triclosan analogs as PfENR inhibitors we 
developed a reliable assay. The experiments were carried out on a BMG LABTECH 
FLUOstar OPTIMA multifunctional microplate reader at 25 OC in 20 mM Tris pH 8.0, 
150 mM NaCl, 10 mM EDTA, 1 mM DTT (buffer D) in a total volume of 200 µL, using 
50 nM PfENR, 400 µM NADH, and 40 µM NAD+. The reaction was started with 
Crotonoyl Coenzyme A (C4CoA) to a final concentration of 300 µM C4CoA per well and, 
detection of the oxidation of NADH to NAD+ was followed at λ= 340 nm using Constar 
96 well plates. 
The dose response curves of enzyme inhibition were followed by measuring the 
effect of an inhibitor on the initial velocity of the enzyme reaction at a fixed 
concentration of substrate. All the inhibitors IC50s (concentration of inhibitor required to 
achieve a half-maximal degree of inhibition) were evaluated from 10 µM to 10 nM, 
Langmuir curves were determined using the program Kaleidagraph 3.5 by fitting the data 
to the equation vi/v0=1/(1+([I]/IC50)) and obtaining the final IC50 value for each inhibitor 
that has a Vi/V0 value less than 0.3 µM. 
 
2.6. Crystallization Condition 
The hanging drop vapor diffusion method was used for the crystallization 
condition, in which 24 mg/mL of PfENR was incubated with 4 mM NADH in buffer D 
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and 2 µL of this mixture was mixed with 2 µL of the well solution consisting of 2.5 M 
(NH4)2SO4, 100 mM NaOAc, and 270 mM tris pH 7.7, and equilibrated at 17 oC, to get 
the binary complex of PfENR-NAD+. Those crystals were used in inhibitor soaking 
experiments, where 2 µL of inhibitor dissolved in 100% acetonitrile were directly added 
to the crystallization drop containing crystals of binary complex with a space group 
P43212 (cell dimension a = b = 132.05 Å, c = 82.84) (Figure 6) to a final concentration of 
2.1 mM, After 7 to 10 days of incubation, crystals soaked with the inhibitor were exposed 
at room temperature in a Rigaku X-ray generator utilizing a copper rotating anode (CuKα 
wavelength = 1.54 Å). Diffraction data was collected from 2.4-Å to 3.1-Å resolution 
from single crystals using a MacScience DIP2030 image plate detector with double-
focusing mirrors. The data were processed and scaled using DENZO/SCALEPACK.11 
 
 
 
 
 
Figure 6. PfENR Crystals, Space Group P43212. 
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CHAPTER III 
STRUCTURAL ANALYSIS OF TRICLOSAN BINDING TO PfENR 
 
 
 
3.1. Introduction 
3.1.1. Mode of Binding of Triclosan to (PfENR)  
Taking into account information derived from the crystal structure of PfENR it is 
known that the active side of this enzyme is mainly constituted by hydrophobic residues: 
Val222, Tyr277, Tyr267, Phe368, Pro314, Gly315, Leu315, His214, Ala217, Asn218, 
Ala219, Lys220, Met231, and Lys285, as is described in Figure 7a and 7b. The α8-Helix 
that forms part of this NAD+-TCL binding pocket is formed by Ala319, Ala320, Ala322, 
Ile323, Ala372, and is represented as lines in some of the figures for better visualization 
of the triclosan and triclosan analogs mode of binding. 
Using the crystal structure obtained for PfENR-NAD+-triclosan complex we have 
found that the phenol ring (ring A) of the inhibitor interacts in an opposite orientation 
with the nicotinamide ring of NAD+ allowing π-cation interactions11. The same ring 
forms additional van der Waals interactions with the side chains of Tyr267, Tyr277, 
Pro314, Phe368, and Ile369. In addition, the phenolic hydroxyl hydrogen-bonds to the 2'-
hydroxyl moiety of the nicotinamide ribose, the oxygen atom of Tyr277, and the amino 
nitrogen of Lys285 is located within 4.65 Å (Figure 7a and 7b). These residues are 
completely conserved in all known ENRs and are thought to have implication in the 
enzyme's catalytic mechanism.11 On the other hand, the ether oxygen atom of triclosan 
interacts with the 2'-hydroxyl group of the nicotinamide ribose, and is located within 
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3.49 Å of one of the oxygen atoms of the nicotinamide ribose phosphate, forming a weak 
hydrogen bond with this group. 
Ring B (2,4-dichlorophenoxy ring) of triclosan is located in a pocket bounded by 
the pyrophosphate and nicotinamide moieties of NAD+, by the peptide backbone residues 
217-231 and by the side chains of Asn218, Val222, Tyr277, and Met281. The 4-chloro 
atom of ring B is placed adjacent to the side chains of Val222 and Met281 and residues 
218-219, the 2-chloro atom is surrounded by the α-carbon atom, the side chain of Ala217, 
and atoms of the nicotinamide ribose pyrophosphate moiety.11 
The chloride atom of ring A at position 5 is surrounded by mainly hydrophobic 
residues making van der Waals contacts with the side chains of Tyr267, Pro314, and 
Phe368. For this study several types of triclosan derivatives were synthesized, mainly to 
make substitutions at positions 1, and 5 of ring A, and 2’ and 4’ of ring B, as well as the 
linker ether group, and some miscellaneous compounds that should resemble the triclosan 
mode of binding to PfENR.  
This chapter describes the results, discussion and implication of the data obtained 
in the whole cell assay, and the enzymatic assays of the different triclosan derivatives 
evaluated in this study. In addition, we describe the crystallographic structure obtained 
for those compounds for which determination of the tertiary complexes bound to PfENR-
NADH crystal structure were possible to obtain.11 
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Figure 7. X-Ray Structure of Triclosan Bound to PfENR. 
(a) Structural representation of triclosan (yellow sticks) and NAD+ (white sticks) bound 
to the active site of PfENR. (b) Structural representation of triclosan and NAD+ showing 
the location of the amino acids (white sticks) at the active side of PfENR and some of the 
interactions that define the mode of binding of triclosan and NAD+, helix α7 is 
represented as lines (green) for better visualization of triclosan and NAD+. 
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Figure 8. Fractional Velocities as Function of Inhibitor Concentration. 
Vi/Vo variation for triclosan and some triclosan derivatives in the PfENR in vitro assay, 
inhibitor JPC-2574-A1 (♦) IC50>100µM has no inhibitory capacity against PfENR, JPC-
2491-A1(■) IC50 41.5µM and JPC-2311-A1(▲) IC50 22.5µM have a moderate inhibition 
of PfENR, JPC-2241-A1 (×) IC50 4.26µM is an acceptable inhibitor, JPC-2187-A1 (*) 
IC50 0.36µM shows to be potent inhibitors and JPC-2603-A1 (●) IC50 0.063µM was as 
good as triclosan (-) IC50 0.034µM 
 
 
To better understand the reported enzymatic data (in vitro evaluation) Figure 8 
represent the variation in inhibitor capacity as function of inhibitor concentration for 
triclosan and some triclosan derivatives, allowing this to further classifies the inhibitors 
as no inhibition, moderate inhibition and potent inhibitory activity against PfENR 
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3.2. Results  
3.2.1. Structural Determination of Triclosan Derivatives (Position 1) 
The hydroxyl group of the phenol ring is essential for triclosan binding; it forms 
hydrogen-bonds with the 2'-hydroxyl group of the nicotinamide ribose and with Tyr277 
(Figure 7a and 7b). Given the metabolic liability in vivo by glucuronidation of triclosan,84 
analogs capable of maintaining or improving these interactions but without the liability 
problem needed to be synthesized. A total of ninety-six triclosan analogs introducing 
hydrophobic (dichlorobenzanilide, naphthy anilide, trifluoromethyl-phenyl-urea, 
benzo[d][1,3]dioxol-6-yl-urea, chlorobenzyl ether and propan-1-ol, among others) and 
hydrophilic (aniline, nitro, trifluoromethyl, or methoxy among others) characteristics at 
position one of triclosan, targeting total or partial replacement of the hydroxyl group of 
ring A, were evaluated for their PfENR inhibitory potency. The objective of this 
evaluation was to seek for hydrogen bonding formation or van der Walls interactions 
between the synthetic analogs and residues in this region of the protein.  
The structure for some of these triclosan derivatives at position one of the A ring, 
the results of whole cell assays (in vivo activity) presented as IC50/ IC90 values for the two 
parasite strains 3D7a (drug-sensitive) and Dd2a (resistant to the antimalarials choroquine, 
pyrimethamine/sulfadoxine), and the enzymatic assays values (in vitro activity) are 
shown in Tables 1,2 and 3. The values obtained were compared with the in vivo (IC50/ 
IC90 = 0.4/0.7 µg/mL for strain 3D7a and 0.9/1.8µg/mL for strain Dd2a) and in vitro 
activities (0.034 µM in the PfENR inhibition assay) measured for triclosan. 
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The inhibitors shown in Table 1 are those containing mainly polar group 
replacements for the hydroxyl group of triclosan. Even though no crystallographic data 
were obtained for these types of triclosan derivatives to show the type of interactions of 
this type of molecule with PfENR-NAD+ binary complex, the poor IC50 values obtained 
for this type of analogs in the enzymatic assay (higher than 50µM), demonstrate that 
replacement of this hydroxyl group have a considerable effect in the inhibition of PfENR 
as consequence there is low or non inhibitory activity of the resulting analogs compared 
with 0.034µM obtained for triclosan. On the other hand, with the exception of JPC-2574-
A1 (0.7/1.4µg/mL and 1.3/3µg/mL) none of the others analogs shows a considerable in 
vivo inhibitory activity against the two strains of the parasite 3D7a and Dd2a. 
Among the ninety-six triclosan analogs evaluated, some had the hydroxyl group 
replaced with an urea group (Table 2). No crystallographic data were obtained for this 
kind of triclosan derivative. However, we inferred that the urea group replacement did 
not generate or maintain the hydrogen bonds with Tyr277 and the 2'-hydroxyl group of 
the nicotinamide ribose in NAD+ required for binding (Figure 7b). These urea derivatives 
could not form any interactions with Tyr267 and Lys285, which are located within 5.33Å 
and 4.41Å of the hydroxyl group of triclosan in the direction which will be occupied by 
this substitution.  
Triclosan derivatives that result from modification of position one with a urea 
group, which we have called urea derivatives, show considerable inhibitory activity in the 
whole cell assay for the two strains of the parasites used (3D7a and Dd2a). The inhibition 
extends from a minimum of 0.02/0.025 µg/mL for strain 3D7a and 0.03/0.05 µg/mL for 
strain Dd2a, (JPC-2201-A1 Table 2) to a maximum of 65.5 µg/mL for strain 3D7a and 
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39.2 µg/mL for strain Dd2a (JPC-1095-A1 Table 3). In addition, compounds like JPC-
2236-A1 also showed a potent parasite inhibitory activity with an IC50/IC90 value of 
0.04/0.05 µg/mL for strain 3D7a and 0.05/0.05 µg/mL for strain Dd2a 
 
Table 1.Triclosan Analogs at Position 1 (R1) 
O
R2
R3R4
R1
 
 
Compound R1 R2 R3 R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH   Cl  Cl Cl 0.4 / 0.7 0.9 / 1.8 0.034 
 
JPC-2063-A-1 NH2  Cl  Cl Cl 15 / 27.6 16.4/ 24.6 >50 
 
JPC-2064-A-1 NO2  Cl  Cl Cl 9.6 / 21 16.5 / 24 >50 
 
JPC-2130-A1 
 
NH-CH3   Cl  Cl Cl 
 
13/23.4 
 
11.6/22.7 
 
>50 
 
JPC-2132-A1 
COOH
 
 Cl  Cl Cl 
 
23/45.6 
 
19/43 
 
>50 
 
JPC-2133-A1 
CONH2
 
 Cl  Cl Cl 
 
>50/>50 
 
>50/>50 
 
>50 
 
 
JPC-2548-A-1 
 
F3C  Cl  Cl Cl 
 
36/48.6 
 
34.5/48.6 
 
>50 
 
JPC-2574-A-1 
NH2
 
 Cl  Cl Cl 
 
0.7/1.4 
 
1/3 
 
>50 
 
JPC-2577-A-1 O O
 
 Cl  Cl Cl 
 
17.5/38.5 
 
16.6/41 
 
>50 
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Table 2. Triclosan Analogs at Position 1 Urea Class (R1) 
O
R2
R3R4
NH
R1
 
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH  Cl  Cl Cl 0.4 / 0.7 0.9 / 1.8 0.034 
 
JPC-2069-A1 
OCl
Cl  
 Cl  Cl Cl 1.2 / 2.7 1.9 / 4.6 >50 
 
JPC-2070-A1 S
OO
 
 Cl  Cl Cl 14 / 41.6 22 / 46 >50 
 
JPC-2077-A1 
O
 
 Cl  Cl Cl 
 
 
2.2 / 3.4 
 
 
2.5 / 4.4 
 
 
>50 
 
JPC-2080-A1 
N
H
O
 
 Cl  Cl Cl 
 
0.3 / 1 
 
0.5 / 1 
 
>50 
 
JPC-2081-A1 O
O
 
 Cl  Cl Cl 
 
3.3 / 6 
 
4 / 6 
 
>50 
 
JPC-2107-A1 
NO
O
 
 Cl  Cl Cl 
 
17.5 / 29 
 
11.6 / 23 
 
>50 
 
JPC-2201-A1 
N
H
O
Cl
F3C  
 Cl  Cl 
 
 
F3C 
 
 
0.02/0.025 
 
 
0.03/0.05 
 
 
>50 
 
JPC-2215-A1 
N
H
O
Cl
Cl
 
 
OH 
  
Cl 
 
F3C 
 
0.2/0.2 
 
0.1/0.2 
 
8.7 
 
JPC-2219-A1 
N
H
OCl
Cl  
 
Cl 
 
Cl 
 
F3C 
 
0.13/0.19 
 
0.16/0.20 
 
>50 
 
JPC-2236-A1 
N
H
OF3C
F3C  
 
 
Cl 
 
 
Cl 
 
 
F3C 
 
 
0.04/0.05 
 
 
0.05/0.05 
 
>50 
 
JPC-2284-A1 
N
H
O
Cl
CF3
 
 
 
OMe 
 
 
Cl 
 
 
F3C 
 
 
0.08/0.1 
 
 
0.04/0.09 
 
 
>50 
 
 
 41
 
Table 2. Continued 
 
Compound 
R1 R2 R3  
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
JPC-2289-A1 
O
N
H
S
O
O
Cl
 
 
Cl 
 
Cl 
 
F3C 
 
18.0/32.0 
 
13.2/25.6 
 
>50 
 
JPC-2290-A1 
NCN
O
 
 
H 
 
F3C 
 
F3C 
 
1.2/2.0 
 
1.2/3.0 
 
>50 
 
JPC-2314-A1 
N
H
SF3C
F3C  
 
 
Cl 
 
 
Cl 
 
 
F3C 
 
 
0.13/0.19 
 
 
0.1/0.2 
 
 
>50 
 
JPC-2320-A1 
O
O
N
H
O
 
 
 
Cl 
 
 
Cl 
 
 
F3C 
 
 
0.8/1.46 
 
 
1/1.5 
 
 
>50 
 
JPC-2323-A1 
N
H
O
 
 
Cl 
 
Cl 
 
F3C 
 
0.3/0.4 
 
0.3/0.4 
 
>50 
 
 
JPC-2342-A1 
N
H
O
 
 
 
 
Cl 
 
 
 
Cl 
 
 
 
F3C 
 
 
 
0.8/1.5 
 
 
 
1.4/ 3 
 
 
 
>50 
 
JPC-2396-A1 
N
H
OF3C
O2N  
 
Cl 
 
Cl 
 
F3C 
 
0.04/0.05 
 
0.04/0.05 
 
>50 
 
 
JPC-2478-A1 N
H
O
O
 
 
 
 
Cl 
 
 
 
Cl 
 
 
 
F3C 
 
 
 
0.3/0.4 
 
 
 
0.2/0.3 
 
 
 
>50 
 
JPC-2479-A1 
N
H
O
S
F3C
O
O
 
 
 
Cl 
 
 
Cl 
 
 
F3C 
 
 
0.078/0.1 
 
 
0.08/0.1 
 
 
>50 
 
JPC-2485-A1 
N
H
O
F3C
Cl
 
 
 
Cl 
 
 
F3C 
 
 
OF3C 
 
 
0.04/0.08 
 
 
0.07/0.1 
 
 
>50 
 
 
JPC-2559-A1 
N
H
ONC
F
F
F
F
 
 
 
Cl 
 
 
Cl 
 
 
F3C 
 
 
0.1/0.2 
 
 
<0.1/0.2 
 
 
>50 
 
 42
 
Table 3. Triclosan Analogs at Position 1H Substitution (R1) 
O
R2O
R1
R4 R3  
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR 
b 
IC50 
(µM) 
 
triclosan H   Cl  Cl Cl 0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-1093-A-1 
HOOC  
 Cl  Cl Cl >20 / >20 >20 / >20 38 
 
JPC-1095-A-1 H2NOC  
 Cl  Cl Cl 65.5/ > 50 39.2/ > 50 16.3 
 
JPC-2001-A-1 
O
N
O
 
 Cl  Cl Cl 34.4 / >50 36.9 / >50 5.3 
 
JPC-2002-A-1 Cl
Cl
Cl
O
 
 Cl  Cl Cl 20/ 39 20/ 46 10.8 
 
JPC-2019-A-1 
Cl  
 Cl  Cl Cl 4/ 7 2.8±/ 5.6 >10 
 
JPC-2026-A-1 N
O
O  
 Cl  Cl Cl 21/ 38 11/ 37 >50 
 
JPC-2138-A1 OH   Cl  Cl Cl 5.7/11 5.6/12.6 >50 
 
JPC-2139-A1 N
H
CH3
O
 
 Cl  Cl Cl 
 
11.1/24.5 
 
9.8/22 
 
>50 
 
JPC-2577-A-1 
 
O  
 
Cl 
 
Cl 
 
Cl 
 
17.5/38.5 
 
16.6/41.4 
 
>50 
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For the in vitro inhibitory activity assay, the same number of compounds was 
evaluated, and the inhibitory activity ranged from a minimum IC50 of 5.3 µM for 
compound JPC-2001-A1 where a morpholino carbamate replaced the hydroxyl group of 
triclosan (Table 3), to a maximum of 50 µM for most of the compounds where 
transformation of the hydroxyl group at position one of triclosan was made (Tables 1, 2 
and 3). Modifications at this position dramatically decreased the inhibitory activity (IC50) 
of most of these triclosan analogs to PfENR, since this data suggest that any major group 
at this position affects the hydrogen bonding of hydroxyl group at position one of 
triclosan with the 2’ hydroxyl group of the nicotinamide ribose and Tyr277 (Figure 7b), 
as well as the van der Walls interactions of ring A of triclosan with the side chains of 
Tyr267, Tyr277 Pro314, Phe368 and Ile369. We were unable to obtain crystallographic 
data for all of the triclosan analogs at position one, to determine their structure and the 
characteristics of the interactions that can take place among PfENR, NAD+ and the 
triclosan analog. 
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3.2.2 Structural Determination of Triclosan Derivatives (Linker (Ether) Position) 
The ether oxygen atom of triclosan (linker position) interacts with the 2'-hydroxyl 
group of the nicotinamide ribose and approaches it within 3.49 Å of one of the oxygen 
atoms of the nicotinamide ribose phosphate group. A total of one hundred-and-thirty 
triclosan analogs at this position were evaluated with the whole cell assay (in vivo 
activity) as well as with the enzymatic assay (in vitro activity). Parts of the results 
obtained are shown in Tables 4 and 5.  
In one-hundred-and-nine of those analogues, (some of them shown in Table 4), 
the ether group of triclosan was substituted by a urea group in addition to some 
modification on rings A and B, introducing new characteristics to the nature of the 
molecule. These compounds showed an efficient in vivo inhibitory activity in the two 
parasite strains (3D7a and Dd2a) used in the assay. The inhibition ranges from a minimum 
IC50/ IC90 of 0.04/0.05 µg/mL and 0.03/0.05 µg/mL, respectively, for compound JPC-
2417-A1 up to 50 µM for most of the compounds where transformation of the ether 
group at the linker position of triclosan was made, hence, it is approximately ten times 
more potent than triclosan, for which the whole cell activity was 0.4/0.7 µg/mL for strain 
3D7a and 0.9/1.8 µg/mL for strain Dd2a. In this group of inhibitors the maximum value 
attained was greater than 50/50 µg/mL and 50/50 µg/mL for compound JPC-2358-A1 for 
both parasite strains. Moreover, the IC50 values collected in the PfENR assay were higher 
than 50 µM. Therefore, these modifications did not introduce any improvement in the 
inhibitory potential of these analogs compared with an IC50 value of 0.034 µM obtained 
for triclosan. 
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When substituting the ether linkage of triclosan by amino or urea groups, in 
addition to some changes in the structure of rings A and B, there was no significant 
improvement in the inhibitory ability of those derivatives to PfENR, possible due to the 
essential interaction of this ether group with the 2'-hydroxyl group of nicotinamide ribose, 
and one of the oxygen atoms of the nicotinamide ribose phosphate group that could not be 
maintained by this urea linkage group (Figure 7b).  
In twenty-one of the linker analogs where the ether group of triclosan was 
substituted by an amino group and the main characteristic groups in ring A and B of 
triclosan were maintained intact (Table 5), we found satisfactory in vivo inhibitory 
activity in the two strains of the parasite 3D7a and Dd2a used in this study. The in vivo 
inhibitory activity ranges from a minimum IC50/IC90 of 0.15/0.4 µg/mL and 0.1/0.4 
µg/mL, respectively, for compound JPC-2578-A1, this value is slightly better than 
triclosan, to a maximum of 30/>50 µg/mL and 24/38 µg/mL for compound JPC-2579-A1 
in both strains of the parasite (Table 5). In the case of the enzymatic inhibitory activity 
with these analogs, the minimum IC50 was 0.046 µM, value as potent as triclosan for 
inhibitor JPC-2578-A1 and the maximum was 18.7 µM for compound JPC-2579-A1.  
These compounds may still be capable of maintaining the interactions of the 
linker group with 2'-hydroxyl group of the nicotinamide ribose, given the hydrogen 
bonding characteristics of the amino linker group, in comparison to the miscellaneous 
linker analogues which most of then presented a value of 50 µM for the enzymatic assay 
in this series of inhibitors (Table 5). 
Considering the result discussed above, it can be suggested that substitutions of 
the ether atom at this linker position connecting ring A and ring B of triclosan for larger 
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modifications, such as substitutions with aniline-nitroethylene (JPC-2533-A1), thiourea 
(JPC-2418-A1), and cyano guanidine (JPC-2317-A1), among others (Table 5), affect the 
interaction of these derivatives with PfENR. However small modifications, such as an 
amino group substitution, still maintains some characteristics of the total inhibitory 
potential of triclosan. None of the triclosan analogs at this position were able to produce 
the satisfactory result in the soaking experiments, to be able to determine their structure 
and characteristics of the mode of interactions. 
 
Table 4. Triclosan Analogs at Linker Position (R1 and R2) 
 
N
H
O
N
H
R2R1
 
 
 
Compound R1 R2 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan   0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-2065-A1 
Cl  
Cl
Cl  
0.3 / 0.7 0.3 / 0.5 >50 
 
JPC-2220-A1 
Cl
F3C
 Cl  
0.5/0.8 0.5/0.7 
 
 
>50 
 
JPC-2221-A1 
Cl
Cl  N  
7.4/12 6 / 19 >50 
 
JPC-2230-A1 
Cl
Cl
 
 
 
 
1.4/ 3 
 
 
1 / 3 
 
 
>50 
 
 
JPC-2250-A1 
CF3
F3C
 
CF3
O
O
 
 
 
 
0.1/0.1 
 
 
 
0.1/0.1 
 
 
 
>50 
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Table 4. Continued 
 
Compound 
R1 R2 3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
 
JPC-2257-A1 
F3C
Cl  
CF3
F
 
 
 
0.2/0.2 
 
 
 
0.2/0.2 
 
 
>50 
 
JPC-2298-A1 
CF3
 
CF3
Cl  
 
1.3/2.6 
 
1.3/2.7 
 
>50 
 
JPC-2358-A1 
CF3
Cl
 
N
 
 
 
>50/>50 
 
 
>50/>50 
 
 
>50 
 
JPC-2366-A1 
N
 
CF3
Cl
 
 
 
4/6 
 
 
3/6 
 
 
>50 
 
JPC-2412-A1 
Cl
F3C  
N N
N
N
H
 
 
 
15/>50 
 
 
39/>50 
 
 
>50 
 
 
 
JPC-2414-A1 
Cl
F3C  
N
CF3
 
 
 
 
0.15/0.2 
 
 
 
0.1/0.2 
 
 
 
>50 
 
 
JPC-2417-A1 
CF3
F3C
 CF3
Cl
 
 
 
0.04/0.05 
 
 
0.03/0.05 
 
 
>50 
 
 
JPC-2427-A1 Cl
F3C
 
N
N
 
 
 
0.2/0.3 
 
 
0.2/0.3 
 
 
>50 
 
JPC-2430-A1 
O
 
CN  
 
 
0.6/0.8 
 
 
0.4/0.76 
 
 
 
>50 
 
JPC-2439-A1 
O  
Cl
CF3
 
 
 
2/3 
 
 
2/3 
 
 
>50 
 
JPC-2463-A1 
Cl
F3C  
NH2
 
 
 
1.7/6 
 
 
2.5/6.2 
 
 
>50 
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Table 5. Triclosan Analogs at Linker Position (Linker Miscellaneous) 
 
 
Compound R 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(nM) 
 
triclosan  0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
 
JPC-2266-A1 N
O
N
Cl
H
CF3F3C
 
 
 
0.3/0.7 
 
 
0.3/0.4 
 
 
>50 
 
 
 
JPC-2317-A1 N
N
N
CF3
H H
CN
CF3
Cl
 
 
 
0.6/2.4 
 
 
0.8/2.7 
 
 
>50 
 
 
JPC-2371-A1 
N
H
N
H
O
Cl
CF3
 
 
 
0.6/1.0 
 
 
0.5/0.8 
 
 
>50 
 
 
 
JPC-2418-A3 
N
H
N
H
S
Cl
CF3
F3C
Cl
 
 
 
0.3/0.4 
 
 
0.3/0.4 
 
 
>50 
 
 
 
 
JPC-2533-A1 
CF3
Cl
N
H
N
H
NO2
CF3
O
Cl
Cl
 
 
 
 
 
1.2/2.6 
 
 
 
 
1/3 
 
 
 
 
>20 
 
JPC-2578-A1 NH
Cl
OH Cl
Cl  
 
 
0.15/0.4 
 
 
0.1/0.4 
 
 
0.046 
 
 
JPC-2579-A1 N
H
Cl
ClO
Cl  
 
 
30/>50 
 
 
24/38 
 
 
18.7 
 
 
JPC-2602-A1 
N
Cl
Cl
Cl
OH
 
   
 
3.7 
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3.2.3 Structural Determination of Triclosan Derivatives (Positions 2’ and 4’) 
The two chloride atoms in positions 2’ and 4’ of ring B are located in a pocket 
bound by the pyrophosphate and nicotinamide moieties of NADH, by the peptide 
backbone residues 217-231, and by the side chains of Asn218, Val222, Tyr277, and 
Met281.11 Although, the 4-chloro atom of ring B was placed adjacent to the side chains of 
Val222 and Met281 and residues 218-219, the 2-chloro atom was surrounded by the α-
carbon atom, the side chain of Ala217, and atoms of the nicotinamide ribose 
pyrophosphate moiety (Figure 7). 11 
Tables 6 and 7 show thirty-three triclosan analogs generated by replacement of 
the chloride group at position 2’ of triclosan with hydrophilic moieties (amino, hydroxyl, 
trifluoromethane, phenylsulfonamide aminomethyl,) capable of forming hydrogen 
bonding with residues in the active site of PfENR, and with more hydrophobic groups 
(benzylamino-methyl, phenylpropylamino-methyl, naphthalen-2-yl-methylamino-methyl, 
benzhydrylpiperazin-1-yl-methyl, naphthalen-2-ylmethylamino-methyl) capable of 
forming van der Walls or π stacking interactions with PfENR and or NAD+. 
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Table 6. Triclosan Analogs at Position 2’ (R2) 
O
R4
R1 R2
R3  
 
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR 
IC50 
(µM) 
 
triclosan OH  Cl  Cl Cl 0.4/0.7 0.9/2 0.034 
 
JPC-2205-A1 
 
OH NH2 H 
 
Cl 13/35 22/40 11.4 
 
JPC-2210-A1 
 
OH 
NH2
 
H Cl 2/8 1.5/4 >50 
 
JPC-2239-A1 
 
 
OH N
H
 
 
 
H 
 
 
Cl 
 
>0.2/>0.2 
 
 
0.3/0.4 
 
 
>50 
 
JPC-2240-A1 
 
 
OH N
H
 
 
 
H Cl 
 
 
0.1/0.2 
 
 
0.2/0.3 
 
 
>50 
 
JPC-2242-A1 
 
OH 
N
H
 
 
 
H Cl 
 
 
0.1/0.2 
 
 
0.2/0.4 
 
 
>50 
 
JPC-2243-A1 
 
 
OH N
H
 
 
 
H 
 
 
Cl 
 
 
0.2/0.2 
 
 
0.2/0.4 
 
 
>50 
 
 
JPC-2490-A-1 
 
 
OH 
S OO
NH
 
 
 
 
Cl 
 
 
 
Cl 
 
 
 
9.7/16.3 
 
 
 
16.0/26.3 
 
 
 
>50 
 
 
 
JPC-2292-A-1 
 
OH 
NH
NH
O
Cl
CF3
 
 
 
 
CF3 
 
 
 
Cl 
 
 
 
0.1/0.2 
 
 
 
0.08/0.1 
 
 
 
>50 
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Table 6. Continued 
 
Compound 
R1 R2 R3  
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR 
bIC50 
(µM) 
 
 
JPC-2301-A-1 
 
 
 
OH N
H
 
 
 
 
Cl 
 
 
 
Cl 
 
 
 
0.1/0.2 
 
 
 
0.1/0.2 
 
 
 
>50 
 
 
JPC-2303-A-1 
 
 
 
OH 
N
H
 
 
 
 
Cl 
 
 
 
Cl 
 
 
 
0.08/0.18 
 
 
 
0.08/0.16 
 
 
 
>50 
 
JPC-2308-A-1 
 
 
OH N
Cl
 
 
 
Cl 
 
 
Cl 
 
 
0.1/0.2 
 
 
0.1/0.2 
 
 
>50 
 
 
JPC-2280-A-1 
 
 
OH 
NH
 
 
 
CF3 
 
 
Cl 
 
 
0.1/0.3 
 
 
0.1/0.3 
 
 
>50 
 
JPC-2333-A-1 
 
OH 
N
Cl
H
 
 
 
Cl 
 
 
Cl 
 
 
0.2/0.2 
 
 
0.1/0.2 
 
 
>50 
 
JPC-2469-A-1 
 
 
OH N
 
 
 
Cl 
 
 
Cl 
 
 
0.1/0.3 
 
 
<0.1/0.2 
 
 
>50 
 
 
 
JPC-2470-A-1 
 
 
OH 
N
N
 
 
 
Cl 
 
 
Cl 
 
 
1.1/1.5 
 
 
0.7/1.4 
 
 
>50 
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The in vitro and in vivo data obtained for these analogs are compared with those 
for triclosan. For which the inhibitory activity for triclosan in the whole cell assay was 
0.4/0.7 µg/mL for strain 3D7a, 0.9/1.8 µg/mL for strain Dd2a, and for the inhibition assay 
(PfENR activity) the value was 0.034 µM. In the whole cell assay, the minimum 
IC50/IC90 value was 0.08/0.18 µg/mL for compound JPC-2303-A1 in strain 3D7a and 
0.08/0.16 µg/mL for strain Dd2a. However, this compound in the assay against PfENR 
showed no inhibition with an IC50 value of more than 50 µM whereas in the assay against 
the parasite, the maximum IC50/IC90 value was 9.7/16.3 µg/mL and 16.0/26.3 µg/mL for 
strains 3D7a and Dd2a respectively for compound JPC-2490-A1, being this compound 
also not efficient in the enzyme assay with an IC50 higher than 50 µM (Table 6). 
In addition to substitutions at the 2’ position, modifications in the 4’ position were 
also studied. A total of seventeen compounds with these characteristics were evaluated, 
some of which are shown in Table 7. Of these, the minimum IC50 was found in 
compound JPC-2263-A1, where an isopropyl biguanyl substitution was introduced 
instead of the usual chloride group of triclosan. This compound has an IC50/IC90 of 
0.1/1.8 µg/mL for the whole cell assay in strain 3D7a and 0.1/1.5 µg/mL for strain Dd2a.  
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Table 7. Triclosan Analogs at Position 2’ (R2) and 4’ (R3) 
O
R1 R2
R3R4  
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH  Cl  Cl Cl 0.4 / 0.7 0.9/2 0.034 
 
JPC-2205-A1 
 
OH NH2 H 
 
Cl 13/35 22/>50 11.4 
 
JPC-2214-A-1 
 
OH NH2 CF3 
 
Cl 5/7 2.5/5  
 
JPC-2244-A1 
 
OH CF3 CHO 
 
Cl 1.3/3 0.5/0.6 21 
 
JPC-2263-A1 
 
OH  Cl NH N
H
N
H
NH NH
.HCL  
 
Cl 0.1/1.8 0.1/1.5 >50 
 
JPC-2273-A-1 
 
OH 
 
CHO 
 
CF3 
 
Cl 
 
2.7/5.6 
 
5/6 
 
3.9 
 
JPC-2288-A-1 
 
OH 
OH
 
 
CF3 
 
Cl 
 
6/12 
 
9/17 
 
0.173 
 
JPC-2334-A-1 
 
OH 
 
CF3 
O
ONH
N
H
O
 
 
Cl 
 
1.5/3 
 
1.5/3 
 
>50 
 
JPC-2335-A-1 
 
OH 
 
CF3 
N
H
N
H
O
 
 
Cl 
 
1/2 
 
1/3 
 
>50 
 
JPC-2336-A-1 
 
OH 
 
CF3 N
H
N
H
O
N
 
 
Cl 
 
3.5/6 
 
4/6 
 
>50 
 
 
JPC-2343-A-1 
 
 
 
OH 
 
 
 
CF3 NH NH
O
 
 
 
 
Cl 
 
 
 
1.1/1.5 
 
 
 
0.9/1.5 
 
 
 
>50 
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The maximum IC50/IC90 value of 3.5/6 µg/mL and 4/6 µg/mL for the two strains 
in this assay, was found in compound JPC-2336-A-1 where a dimethylamino-phenyl-
urea group in position 4’ was introduced in addition to a trifluoromethyl group in position 
2’ (Table 7). 
In the case of the enzymatic assay, these analogs do not show any inhibitory 
activity. The IC50 value was higher than 50 µM. In addition, replacement of the chloride 
groups at position 2’ and 4’ with small polar groups like -CHO, -NH2, or -CF3 caused 
some effects in the enzymatic assay, in opposition to the value for the whole cell assay 
found in compounds like JPC-2273-A1, IC50/IC90 of 2.7/5.6 µg/mL for strain 3D7a, 
4.8/6.2 µg/mL for strain Dd2a and the IC50 value in the enzymatic assay was 3.9 µM 
(Table 7). Therefore, this compound might be targeting PfENR to some degree judging 
by these in vivo and in vitro activity results, but no crystallographic data has been 
collected after the soaking experiments to define the structure of this compound bound to 
PfENR-NAD+ complex.  
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3.2.4 Structural Determination of Triclosan Derivatives (Position 5 and 4’) 
A total of eighty-nine triclosan analogs, which targeted replacement of the 
chloride atom at 4’ and 5 positions with small polar groups such as -NO2, -NH2 -NHCO,  
-CN, -OH, -F3C, -OCF3, as well as nonpolar groups like, -CH3, phenyl, phenethyl, tolyl, 
benzyl, pyridine, isopentyl, methylbutyl, among others, were synthesized. In some of 
these inhibitors, also the hydroxyl group on position one was modified, resulting in 
considerable variation of the IC50 values. Results in the enzymatic assay are presented in 
Tables 8 and 9 for some of this kind of analogs. Each of these groups introduces possible 
interesting modes of interactions to the resulting triclosan analogs.  
We can divide these eighty-nine analogs in two groups, one group in which forty-
three of them had the replacement taking place in position 4’ and 5 in addition to some 
variation in position 1 and 2’ (Table 8); and the other group of forty-six inhibitors where 
the basic replacement took place at position 4’, where a urea group was modified (Table 
10). Within these eighty-nine analogs, we found the most interesting compounds in the 
entire study, some of which are shown in (Table 8) together with their in vivo and in vitro 
inhibitory activity.  
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Table 8. Triclosan Analogs at Position 4’ (R3) and 5 (R4) 
O
R1 R2
R3R4  
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH Cl  Cl Cl 0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-2134-A1 
 
OH Cl NH2 
 
CH3 33.3/>50 40.6/>50 1.48 
 
JPC-2135-A1 
 
OH Cl NO2 
 
CH3 1.9/3.5 2.3/4.3 >50 
 
JPC-2136-A1 
 
OH 
 
Cl 
 
NH2 
  
Cl 
 
21.7/47 
 
28/>50 
 
0.79 
 
JPC-2137-A1 
 
OH 
 
Cl 
 
NO2 
 
 Cl 
 
0.6/11 
 
0.6/11 
 
0.099 
 
JPC-2140-A1 
 
OH 
 
H 
 
CN 
  
Cl 
 
2.5/5. 
 
2.5/5 
 
0.230 
 
JPC-2141-A1 
 
OH 
 
H 
N
H
N
N
N
 
  
Cl 
 
22/47 
 
35/50 
 
2.4 
 
JPC-2142-A1 
 
OH 
 
H 
O  
  
Cl 
 
2.7/5 
 
7.7/11 
 
0.548 
 
JPC-2149-A1 
 
OH 
  
Cl 
 
CN 
 
 Cl 
 
1.0/1.5 
 
1.7/2.9 
 
0.079 
 
JPC-2150-A1 
 
OH 
  
Cl 
N
H
N
N
N
 
  
Cl 
 
33/41 
 
>50/>50 
 
1.18 
 
JPC-2153-A1 
 
OH 
  
Cl 
N O
O
N
H
 
  
Cl 
 
13/18 
 
26/39 
 
0.909 
 
JPC-2158-A1 
 
OH 
  
Cl 
O
H
 
  
Cl 
 
20/22 
 
34.6/45 
 
0.760 
 
JPC-2159-A1 
 
OH 
 
 Cl 
N
H
O
NH2
 
  
Cl 
 
22/33 
 
48.5/>50 
 
0.044 
 
JPC-2160-A1 
 
OH 
 
Cl SN
H
O
O  
 
 Cl 
 
16/20 
 
25.4/40.7 
 
0.055 
 
JPC-2162-A1 
 
OH 
 
 Cl 
O
N
H
 
 
 Cl 
 
10.4/13 
 
22.2/30 
 
0.143 
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Table 8. Continued 
 
Compound 
R1 R2 R3  
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
JPC-2166-A1 
 
OH 
 
 Cl 
N
H
O  
 
 Cl 
 
10/13.7 
 
19.5/27 
 
0.435 
 
JPC-2168-A1 
 
 
OH 
 
 
 Cl N
O  
 
  
Cl 
 
 
2.7/4 
 
 
9 /6 
 
 
0.792 
 
JPC-2169-A1 
 
 
OH 
 
 
 Cl N
O
O  
  
 
Cl 
 
 
10/16 
 
 
38/26 
 
 
0.187 
 
JPC-2171-A1 
 
 
OH 
 
 Cl N
O  
 
 Cl 
 
5/7 
 
19/13 
 
0.309 
 
JPC-2178-A1 
 
OH 
 
H 
N OH
 
 
Cl 
 
9/ 19 
 
9/ 19 
 
0.320 
 
JPC-2179-A1 
 
OH 
 
Cl 
N
H
 
 
Cl 
 
1/ 2 
 
1/ 2 
 
1.423 
 
JPC-2181-A1 
 
OH 
 
Cl 
 
OH 
 
Cl 
 
13 / 33 
 
12.7/ 26.6 
 
0.177 
 
JPC-2182-A1 
 
OH 
 
Cl 
N
H
O
 
 
Cl 
 
6.5/ 19 
 
4 / 14 
 
0.103 
 
JPC-2190-A1 
 
OH 
 
Cl SN
H
O
O
 
 
 
Cl 
 
 
10.6/ 21 
 
 
10 / 22.7 
 
 
0.665 
 
JPC-2197-A1 
 
OH 
 
H 
OH  
 
Cl 
 
9/21 
 
12/23.7 
 
0.230 
 
JPC-2200-A1 
 
OH 
 
Cl SN
H
O
O
CF3
 
 
Cl 
 
44.2/>50 
 
>50/>50 
 
0.206 
 
JPC-2212-A1 
 
OH 
 
H 
O
NH2
 
 
Cl 
 
23/47 
 
21.4/47 
 
0.052 
 
JPC-2283-A1 
 
OH 
 
Cl 
CN
 
 
Cl 
 
9.6/20 
 
13/24 
 
0.295 
 
JPC-2159-A2 
 
OH 
 
Cl 
N
H
O
NH2
 
 
Cl 
 
47/>50 
 
44.4/>50 
 
0.371 
 
 
JPC-2431-A1 
 
 
Cl 
 
 
H NH
S
N
H
CF3
Cl
 
 
 
 
OCF3 
 
 
0.4/0.7 
 
 
0.5/0.7 
 
 
>50 
 
JPC-2545-A1 
 
OH 
 
H 
 
CF3  
 
Cl 
 
0.6/1.5 
 
0.8/2 
 
0.210 
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The results have illustrated that, even though the whole cell assay for some of 
those compounds had a maximum IC50/IC90 value for the inhibition in the two strains of 
>50/>50 µg/mL and more than 50 µM on the enzymatic assay for most of them, for many 
of these triclosan analogs at position 5 and 4’the enzymatic inhibitory activity was less 
than 1 µM. For instance, there were values like 0.044 µM in the case of compound JPC-
2159-A1 where a urea group substituted the chloride at position 4’ almost as potent as 
triclosan, but has a whole cell IC50/IC90 value of 22/33 µg/mL for strain 3D7a 
(chloroquine sensitive) and 48.5/>50 µg/mL for strain Dd2a (chloroquine resistant). 
Meanwhile, compound JPC-2305-A1 where a tolyl group was substituted for the 
chloride at position 5 of triclosan shown a considerable inhibition in both the parasite and 
the PfENR assay, it display an IC50 of 0.17 µM five times less potent than triclosan in the 
enzyme assay, and a minimum IC50/IC90 value of 0.7/1.4 µg/mL and 1.3/2.8 µg/mL 
almost as effective as triclosan for the two strains in the whole cell assay (Table 9). One 
of the minimum values in the enzymatic inhibitory activity was 0.049 µM for compound 
JPC-2573-A1 where an ethyl group substitutes for the chloride at position 5, with whole 
cell IC50/IC90 values for the strains used in this study of 14/3 µg/mL and 1/4.6 µg/mL, 
respectively. 
It was only possible to collect crystallographic data for some triclosan analogs 
modified at the 4’ and 5 positions, therefore, crystals of the tertiary complex of PfENR-
NAD+-inhibitor were obtained. Figures 9-13 show the mode of interactions for six of 
these inhibitors, where the π- π stacking interaction with the nicotinamide ring of NAD+, 
the hydrogen-bonding with the 2'-hydroxyl group of the nicotinamide ribose and with 
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Tyr277 as well as Van der Waals interactions of ring A with the side chains of Tyr267, 
Tyr277, Pro314, Phe368, and Ile369 were maintained. Furthermore, depending on the 
replacement group on position 4’ the hydrogen bonds to the residues Asn218, Ala219 
were created. 
The structure in Figure 9 represents the mode of binding of compound JPC-2136-
A1 and JPC-2137-A1, where most of the binding characteristics of triclosan are 
conserved. In these two compounds, only the 4’ chloride group of triclosan was changed 
for an amino group. Compound JPC-2136-A1 (Figure 9) had an IC50/ IC90 of 21.7/47.1 
µg/mL for strain 3D7a, 27.8/>50 µg/mL for strain Dd2a in the whole cell assay and, 0.79 
µM almost 20 times less active than triclosan in both the whole cell and the PfENR assay. 
From Figure 9 we can determine the binding characteristics of compound JPC-
2136-A1, where there is the typical π-π stacking interaction of the analogs with the 
nicotinamide ring of NAD+ as well as the van der Waals interactions with the side chains 
of Tyr267, Tyr277, Pro314, Phe368, and Ile369, besides the interaction of the phenolic 
hydroxyl that forms hydrogen bonds with the 2'-hydroxyl moiety of the nicotinamide 
ribose (distance O=O = 2.95 Å), the oxygen atom of Tyr277 (distance O=O = 2.75 Å) and 
the amino nitrogen of Lys285. However, the main characteristic for the interaction of this 
compound with PfENR is that the aniline hydrogen’s are hydrogen-bonded with the side 
chain carbonyl of Asn218 (distance C=O-N = 3.34 Å), the main chain carbonyl of Ala219 
(distance C=O-N =3.7 Å) and it has favorable interaction with the main chain N-H group of 
Ala219 (distance N-N = 2.7 Å) (Figure 7). 
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Figure 9 X-Ray Structure of (JPC-2136-A1) and (JPC-2137-A1) Bound to PfENR. 
Stick drawing (yellow) for compound (JPC-2136-A1) and (JPC-2137-A1) in the PfENR 
(green cartoon representation) –NADH (white sticks) complex and stick format for amino 
acids at this region, red dots represent the hydrogen bonds interactions. Helix α7 is 
represented as green lines for better visualization of JPC-2136 and NAD+. 
JPC-2136
Lys 220
Ala 219
Asn 218
Ala 217
Tyr 277
NAD+
O
OH
Cl
Cl
NH2
O
OH
Cl
Cl
NO2
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Compound JPC-2137-A1 has the same binding characteristics that JPC-2136-
A1. However the crystal structure, in this case, shows that the side chain of Asn218 
rotates allowing its carboxamide N-H to interact with one of the nitro oxygen’s while the 
other nitro oxygen forms a hydrogen bond with the main chain N-H group of Ala219 
(distance N-O = 3.2 Å) (Figure 9). The IC50/ IC90 value for this compound was 0.6/11.2 
µg/mL for strain 3D7a, 0.6/11.3 µg/mL for strain Dd2a and 0.099 µM in the enzymatic 
assay, only three times less active than triclosan (Table 8). 
Figure 10 shows the mode of binding of compound JPC-2141-A1 to PfENR. This 
compound has an IC50 of 22.3/47.4 µg/mL for strain 3D7a and 34.7/>50 µg/mL for strain 
Dd2a in the whole cell assay (almost 50 times less potent than triclosan) in addition to 2.8 
µM in the enzymatic assay (10 times less potent than triclosan) (Table 8). It also 
maintains the same binding characteristics of triclosan, such π-π stacking interaction of 
the analog with the nicotinamide ring of NADH, van der Waals interactions with the side 
chains of Tyr267, Tyr277, Pro314, Phe368, and Ile369, and the interaction of the 
phenolic hydroxyl that form hydrogen bonds with the 2'-hydroxyl moiety of the 
nicotinamide ribose, the oxygen atom of Tyr277, and the amino nitrogen of Lys285. The 
oxygen linker atom interacts with the 2'-hydroxyl group of the nicotinamide ribose and 
one of the oxygen atoms of the nicotinamide ribose phosphate. The 2-chloro atom was 
surrounded by the α-carbon atom, the side chain of Ala217, and atoms of the 
nicotinamide ribose pyrophosphate moiety. 
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This 4’ tetrazol position analog is placed adjacent to the side chains of Val222 and 
Met281 and residues 218-219. The interaction of the phenolic hydroxyl forms hydrogen 
bonds with the 2'-hydroxyl moiety of the nicotinamide ribose (distance O=O = 2.73 Å) and 
the oxygen atom of Tyr277 (distance O=O = 2.79 Å). However, the main characteristics 
for the interactions in this compound with PfENR is that one of the tetrazol nitrogen’s has 
a weak hydrogen-bonded interaction with the side chain carbonyl of Asn218 (distance 
C=O-N = 4.04 Å), while the others have hydrogen-bonded interaction with the main chain 
group N-H of Ala219 (distance N-N =2.91 Å) and with the side chain carbonyl of Ala219 
(distance C=O-N = 2.7 Å). While the IC50 value for this inhibitor in the enzymatic assay 
shows that it is almost 100 times less active than triclosan, we were still able to determine 
the characteristics of its interactions with PfENR-NAD+ complex. (Figure 10) 
Compound JPC-2166-A1 (Table 8) is a derivative where an N-methylamide 
group is substituted for the chloride group at position 4’ in triclosan. This compound has 
an IC50/IC90 value of 10/13.7 µg/mL for strain 3D7a, 19.5/26.8 µg/mL for strain Dd2a in 
the whole cell assay and 0.435 µM in the enzymatic assay (Table 8). Even though the 
whole cell assay is more than 30 times less effective than triclosan, still the enzyme 
inhibitory activity is 10 folds less potent than triclosan, despite of this, we were able to 
determine the mode of binding of this compound (Figure 11) which does not differ much 
compared to the mode of binding of triclosan and the other inhibitors discussed thus far.  
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Figure 10 X-Ray Structure of (JPC-2141-A1) Bound to PfENR. 
Stick drawing (yellow) for compound (JPC-2141-A1) in the PfENR (green cartoon 
representation) –NADH (white sticks) complex and stick format for amino acids at this 
region, red dots represent the hydrogen bonds interactions, Helix α7 is represented as 
green lines for better visualization of the inhibitor and NAD+. 
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The π-π stacking interaction of ring A of the analog with the nicotinamide ring of 
NAD+ is maintained as well as the hydrogen bond interaction of the hydroxyl group in 
ring A of compound JPC-2166-A1 with Tyr277 (distance O=O = 2.57 Å) and the 2'-
hydroxyl moiety of the nicotinamide ribose (distance O=O = 2.95 Å). The ether oxygen 
atom linker of ring A and B still interact with the 2'-hydroxyl group of the nicotinamide 
ribose, and one of the oxygen atoms of the nicotinamide ribose phosphate (Figure 11). In 
addition, the carbonyl group of the N-methylamide substitution in position 4’ of triclosan 
makes a weak hydrogen bond with the side chain N-H of Asn218 (distance O=N = 4.14 Å) 
and with the backbone N-H of Ala219 (distance O=N = 3.54 Å). The amide methyl group 
interacts with the Val222 side chain (Figure 11). 
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Figure 11 X-Ray Structure of (JPC-2166-A1) Bound to PfENR. 
Stick drawing (yellow) for compound (JPC-2166-A1) in the PfENR (green cartoon 
representation) –NADH (white sticks) complex and stick format for amino acids at this 
region, red dots represent the hydrogen bonds interactions, Helix α7 is represented as 
green lines for better visualization of the inhibitor and NAD+. 
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A morpholine-carboxylic acid amide substitution was introduced at position 4’ of 
triclosan to determine the binding capacity and characteristics of this triclosan analog. 
Compound JPC-2153-A1 has an IC50/ IC90 value of 13.1/18.2 µg/mL for strain 3D7a and 
26.2/39.3 µg/mL for strain Dd2a (50 times less potent than triclosan) in the whole cell 
assay, even though the IC50 value obtained in the enzymatic assay was 0.91 µM (Table 8) 
thirty times less active than triclosan. With this molecule, we were able to determine the 
characteristics of the binding of this triclosan analog to PfENR as it is shown in Figure 
12. The π-π stacking interaction of ring A of the analog JPC-2153-A1 with the 
nicotinamide ring of NAD+ is maintained as well as the hydrogen bond interaction of the 
hydroxyl group in ring A of compound JPC-2153-A1 with Tyr277 (distance O=O = 
2.55Å) and the 2'-hydroxyl moiety of the nicotinamide ribose (distance O=O = 2.54Å). The 
ether oxygen atom linker of ring A and B still interact with the 2'-hydroxyl group of the 
nicotinamide ribose and one of the oxygen atoms of the nicotinamide ribose phosphate 
(Figure 12). 
The 4’ urea carbonyl group is hydrogen bonded with the side chain N-H of 
Asn218 (distance C=O-N = 2.76Å), and the backbone N-H of Ala219 (distance C=O-N = 
2.98Å). Figure 12 shows in two orientations front and side view, the binding of JPC-
2153-A1. The additional characteristics of the interactions of this molecule compared to 
those for triclosan to PfENR are that the carboxylic group of the morpholine-carboxylic 
acid amide forms an additional hydrogen bond with Asn218 and Ala219. Even though 
compound JPC-2153-A1 has around 30 times less inhibitory capacity than triclosan, it 
gives more information about the interaction in the binding pocket of PfENR, being 
capable of accepting different kind of inhibitors derived from the triclosan scaffold. 
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Figure 12 X-Ray Structure of (JPC-2153-A1) Bound to PfENR. 
Stick drawing (yellow) for compound (JPC-2153-A1) in the PfENR (green cartoon 
representation) –NADH (white sticks) complex and stick format for amino acids at this 
region, red dots represent the hydrogen bonds interactions, Helix α7 is represented as 
green lines for better visualization of the inhibitor and NAD+. 
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One of the most interesting results in this research is the elucidation of the 
structure of compound JPC-2305-A1 bound to PfENR-NAD+ complex. This analog 
(Figure 13) has an IC50 five times less active (0.17 µM) than triclosan (0.034 µM) in the 
enzymatic assay, but in the whole cell assay it is two times as potent as triclosan 
exhibiting an IC50/ IC90 value of 0.7/1.4 µg/mL for the strain 3D7a, and 1.3/2.8 µg/mL for 
strain Dd2a (Table 9). 
This compound was designed based on the mode of binding of isonicotinic acyl-
NAD+ to the active site of PfENR. This is an adduct molecule that is the product of the 
activation of isoniazid in the active site of InhA in presence of KatG and NADH. This 
adduct produces a conformational change on residue Tyr267 in PfENR.76,88 
We used this information to substitute the chloride group in position 5 of triclosan for an 
o-tolyl group. This substitution in triclosan, in fact, introduced a conformational change 
in the active site of PfENR, producing a flipping movement of about 45 degrees in 
residue Tyr267 (Figure 13). 
As is shown in Figure 13 the π-π stacking interaction of ring A of the analog 
JPC-2305-A1 with the nicotinamide ring of NAD+ is maintained, in addition to a π-π 
stacking interaction of the o-tolyl group with Tyr267, Tyr277 still forms the hydrogen 
bond interaction of the hydroxyl group in ring A of compound JPC-2305-A1 with 
Tyr277 (distance O=O = 2.58Å) and the 2'-hydroxyl moiety of the nicotinamide ribose 
(distance O=O = 2.55Å). The ether oxygen atom linker of ring A and B still interacts with 
the 2'-hydroxyl group of the nicotinamide ribose and one of the oxygen atoms of the 
nicotinamide ribose phosphate (Figure 13). 
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The information obtained from the elucidation of the mode of binding of 
compound (JPC-2305-A1) allowed the design of a new series of triclosan analogs that 
have IC50 values for the in vitro assay closer to the 0.034 µM found for triclosan, and 
introduced a new type of interaction for these types of analogs, some of which are shown 
in Table 9, where the common characteristics of triclosan binding to PfENR are 
maintained. 
 
Table 9. Triclosan Analogs at Position 5 (R4) 
O
R1 R2
R3R4  
 
Compound R1 R2 R3 
 
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH Cl Cl Cl 0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-2163-A1 
 
OH Cl Cl 
 
 
1/2 
 
2/3 
 
0.257 
 
JPC-2187-A1 
 
OH Cl Cl 
 
NO2 
 
3 / 4.6 
 
10/ 28 
 
6.77 
 
JPC-2278-A1 
 
 
OH 
 
Cl 
 
Cl 
 
 
1.3/3 
 
2.2/3 
 
1.4 
 
JPC-2279-A1 
 
 
OH Cl Cl 
 
 
 
1/3 
 
 
2.8/5.6 
 
 
4.6 
 
JPC-2305-A1 
 
 
OH Cl Cl 
 
 
 
0.7/1.4 
 
 
1/2.8 
 
 
0.17 
 
JPC-2315-A1 
 
 
OH 
 
Cl 
 
Cl OH  
 
 
37.7/>50 
 
 
38.7/>50 
 
 
1.29 
 
JPC-2380-A1 
 
CF3 
 
Cl 
 
Cl 
S
NN
N
H
O
N
H  
 
1.6/3 
 
1/1.6 
 
>50 
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Table 9. Continued 
 
Compound 
R1 R2 R3  
R4 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
 
JPC-2448-A1 
 
OH Cl Cl 
 
 
2.5/4 
 
3.7/6 
 
0.139 
 
 
JPC-2471-A1 
 
 
OH 
 
 
H 
 
 
H 
 
 
 
4.6/6 
 
 
5.6/11 
 
 
0.232 
 
JPC-2472-A1 
 
OH Cl Cl 
 
 
4/6 
 
5/11 
 
0.132 
 
JPC-2489-A1 
 
OH Cl Cl 
 
 
0.7/2 
 
1/2 
 
0.98 
 
JPC-2492-A1 
 
OH Cl Cl 
N  
 
2.7/6 
 
5/10 
 
0.397 
 
JPC-2501-A1 
 
OH Cl Cl 
N
 
 
2.5/5 
 
4.7/6 
 
0.173 
 
JPC-2530-A1 
 
OH 
 
Cl 
 
CN 
N
 
 
3/5 
 
4/6 
 
0.654 
 
JPC-2551-A1 
 
 
OH 
 
 
Cl 
 
 
CN 
CH3
 
 
 
1/1.6 
 
 
1 /1.6 
 
 
0.24 
 
JPC-2571-A1 
 
 
 
OH 
 
 
Cl 
 
 
Cl 
 
 
 
1 2.8 
 
1/3 
 
0.328 
 
JPC-2572-A1 
 
 
OH 
 
Cl 
 
Cl 
 
 
 
0.9/2 
 
0.8/2.7 
 
0.161 
 
JPC-2573-A1 
 
OH 
 
Cl 
 
Cl 
 
 
 
14/3 
 
1/4.6 
 
0.0494 
 
JPC-2575-A1 
 
OH 
 
Cl 
 
CN N
 
 
2./5.6 
 
3 /10 
 
0.238 
 
JPC-2589-A1 
 
OH 
 
Cl 
 
Cl 
 
 
1.4/3 
 
1.8/3 
 
0.269 
 
JPC-2591-A1 
 
OH 
 
Cl 
 
Cl 
 
 
0.7/1.8 
 
1/2.5 
 
0.268 
 
JPC-2592-A1 
 
OH 
 
Cl 
 
Cl 
 
 
4/8 
 
5/11 
 
0.662 
 
JPC-2603-A1 
 
OH 
 
Cl 
 
Cl 
 
I 
   
0.063 
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Figure 13 X-Ray Structure of (JPC-2305-A1) Bound to PfENR. 
Stick drawing (yellow) for compound (JPC-2305-A1) in the PfENR (green cartoon 
representation) –NADH (white sticks) complex and stick format for amino acids at this 
region, red dots represent the hydrogen bonds interactions, Helix α7 is represented as 
green lines for better visualization of the inhibitor and NAD+. 
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3.2.5. Structural Determination of Triclosan Derivatives in Every Position  
At this point in the project we were trying to get as many diverse triclosan 
derivatives as possible. Therefore, Twenty-one analogs, where variations in all positions 
on both rings were made, can be seen in Table 10. Substitution of the chloride atoms in 
both rings for small group such as Br, F, H, -CF3 -NO2, -NH2, -CH3 -CN, -OCH3 were 
made as well as some phenyl, pyridin and allyl substitutions.  
Compound JPC-2588-A1 displayed the worst IC50/ IC90 value for the whole cell 
assay 12.5/24.5 µg/mL for strain 3D7a and 12.3/23.9 µg/mL for strain Dd2a, in which a 
chloride and iodine group were placed in position 4 and 6 of ring A of triclosan (Table 
10). Compound JPC-2588-A1 shows the poorest IC50 (>50 µM) for the enzymatic assay 
in this series of compound. The minimum IC50/ IC90 value for the whole cell assay 
compound JPC-2327-A1 was 0.6/1 µg/mL and 0.85/1.5 µg/mL for strains 3D7a and Dd2a 
very close to that exhibit by triclosan, with an inhibitory value almost ten times less 
potent than triclosan in the enzyme assay (0.28 µM) (Table 10). Additionally, we found 
in the enzymatic assay that compound JPC-2603-A1 showed a minimum IC50 value of 
0.063 µM, and several others presented a value higher than 50 µM.  
As a result, variations in any position of triclosan did not introduce a very 
significant improvement in the inhibitor efficiency of these analogs (Table 10). This 
result illustrate that, the compounds described in Table 10 are inhibiting PfENR due to 
their structure conserve the same characteristics of triclosan scaffold. Unluckily, no 
crystallographic data was collected after the soaking experiments to define the structure 
of this compound bound to PfENR-NAD+ complex. 
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Table 10. Triclosan Analogs at All Positions 
O
R1 R2
R3
R4
R5R6
R7
R8
 
 
Compound R1 R2 R3 
 
R4 R5 R6 R7 
 
R8 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan OH Cl H Cl H H Cl H 0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-2155-A1 OH H H CN H OCF3 H H 2.3/5.3 6.1/11.9 2.19 
 
JPC-2161-A-1 OH Cl H Cl H Br CH3 H 0.6/1.2 1.3/1.6 1.45 
 
JPC-2165-A1  OH 
 
H 
 
Br 
 
NO2 
 
H 
 
H 
 
Cl 
 
H 1.3/2.6 2.8/5.4 0.41 
 
JPC-2204-A1 
 
NH2 
 
CH3 
 
H 
 
Cl H H CF3 
 
H 0.4 / 0.7 1 / 2 >50 
 
JPC-2275-A1 OH Cl 
 
H 
 
Cl 
 
H 
 
 
Cl 
 
 
3.5/6.4 
 
5/7 
 
>20 
 
JPC-2281-A1 OH Cl 
 
H 
 
Cl H O
 
Cl 
 
H 
 
9.6/18 
 
9.6/20 
 
21.4 
 
JPC-2327-A1 OH Cl 
 
H 
 
Cl H H Cl 
 
 
0.6/1 
 
0.85/1.5 
 
0.280 
 
JPC-2566-A-1 
 
OH 
 
H 
 
H 
 
NO2 H CF3 H 
 
H 
 
1/3 
 
1/4 
 
0.174 
 
JPC-2598-A1 
 
 
OH 
 
 
Cl 
 
 
H 
 
 
Cl 
 
 
H 
 
 
Cl 
 
 
Cl 
N
 
5/10 4/11 4.070 
 
JPC-2588-A-1 
 
OH 
 
Cl 
 
H 
 
Cl 
 
H 
 
Cl 
 
Cl 
 
I 12.52/24.54 12.30/23.92 >50 
 
JPC-2601-A1 
 
OH 
 
Cl 
 
H 
 
Cl 
 
H 
 
 
Cl 
 
H 
   
 
1.4 
 
JPC-2603-A1 
 
OH 
 
Cl 
 
H 
 
Cl 
 
H 
 
H 
 
I 
 
H 
   
0.063 
 
JPC-2604-A1 
 
OH 
 
Cl 
 
H 
 
Cl 
 
H 
 
Cl 
 
Cl 
 
Br 
   
0.099 
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3.2.6 Structural Determination of Miscellaneous Triclosan Derivatives 
Other possible PfENR inhibitors evaluated in this study are triclosan derivatives 
which do not totally resemble the ring A and B structure of triclosan, we have denoted 
those as miscellaneous analogs (Table 11). This type of analogs was thought to fit in the 
inhibitor binding pocket in PfENR. Eighty-seven analogues of this type were evaluated 
and we found that the minimum IC50/IC90 value for the whole cell assay for compound 
JPC-2506-A1 (0.04/0.07 µg/mL for strains 3D7a and 0.07/0.16 µg/mL for strains Dd2a) 
was ten times more potent than triclosan. However, this compound has an IC50 value for 
the enzymatic assay higher than 50 µM.  
On the other hand, the maximum IC50/IC90 value for the whole cell assay was 
found to be higher than 50/50 µg/mL for both strains 3D7a and Dd2a in several 
compounds in this series. For the enzymatic assay, we found that the maximum IC50 
value for most of the compounds in this series was higher than 50 µM, and the minimum 
was 0.28 µM (approximately ten times less potent than triclosan) for compound JPC-
2195-A1 and a whole cell IC50/IC90 value of 6/12 µg/mL for strain 3D7a and 14/23 
µg/mL for Dd2a. This value for the enzymatic assay is not surprising due to the fact that 
this compound still conserves some characteristics of the triclosan scaffold, such as the 
chlorophenol ring A required for the inhibitory activity of this type of compounds (Table 
11). Other miscellaneous inhibitor which showed considerable inhibitory activity were: 
compound JPC-2147-A1 with an IC50 value of 0.57 µM, compound JPC-2188-A1 with 
an IC50 value of 3.3 µM, compounds JPC-2128-A1 with an IC50 of 21.4 µM. In addition 
compound JPC-2129-A1 with an IC50 of 17 µM and compound JPC-2209-A1 with an 
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IC50 of 13.8 µM are the most significant considering the variation of the triclosan scaffold 
that could affect the interactions of this molecule with PfENR-NAD+ complex. 
 
Table 11. Miscellaneous Triclosan Analogs 
 
 
Compound R 
3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
triclosan O
Cl
ClCl
OH
 
0.4±0.1 / 0.7±0.1 0.9±0.1 / 1.8±0.3 0.034 
 
JPC-2072-A1 
CCl3
Cl3C
 
0.4 / 2.6 0.3 / 1 >50 
 
JPC-2074-A1 
COOH
ClCl  
 
 
7.7 / 13.6 
 
 
7 / 12 
 
 
>50 
 
 
JPC-2075-A1 O
O
O
OOH
 
 
 
 
 
30±7 / >50 
 
 
 
 
>50 / >50 
 
 
 
 
>50 
 
 
JPC-2089-A1 
Cl
O
COOH
CN
 
 
 
48.6 / >50 
 
 
48.0 / >50 
 
 
>50 
 
 
JPC-2092-B1 
N
N
O
O
O
O
Cl
 
 
 
 
40 / >50 
 
 
 
35 / >50 
 
 
 
 
>50 
 
 
JPC-2093-A1 
N
N
O
 
 
 
 
35 / >50 
 
 
 
24 / >50 
 
 
 
>50 
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Table 11. Continued 
 
Compound 
R 3D7 a 
EC50 / EC90 
(µg/mL) 
Dd2 a 
EC50 / EC90 
(µg/mL) 
PfENR b 
IC50 
(µM) 
 
 
JPC-2108-A1 
N
O
Cl
O
Cl
Cl
O
 
 
 
1 / 4 
 
 
0.6 / 1 
 
 
>50 
 
 
JPC-2116-A1 N N
O
Cl
Cl
 
 
 
13 / 27.5 
 
 
10 / 21 
 
 
>50 
 
 
JPC-2117-A1 
N
N
O
N
H
Cl
Cl
Cl
 
 
 
6.5 / 17 
 
 
4.6 / 9 
 
 
>50 
 
JPC-2124-A1 
Cl
N
H
O
OH
O  
 
5/10 
 
1/19 
 
>50 
 
 
 
JPC2128-A1 
N
O
N
NH
 
 
 
 
4.6/8.7 
 
 
 
4/6 
 
 
 
21.4 
 
 
 
JPC-2129-A1 
N
O
N
NH
 
 
 
 
10/21 
 
 
 
7/18 
 
 
 
17 
 
 
JPC-2147-A1 
O
OH
Cl OH  
 
 
9/8 
 
 
19/21 
 
 
0.570 
 
 
JPC-2164-A1 
O
OH
Cl O
O
N
H  
 
 
12/18 
 
 
25/42 
 
 
9.7 
 
JPC-2185-A1 
N
N
O
ClCl
OH
 
 
 
21/48 
 
 
30/50 
 
 
17.7 
 
JPC-2188-A1 
N
N
O
Cl
OH Cl
 
 
1/ 2 
 
2/ 4 
 
3.32 
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Table 11. Continued 
 
 
JPC-2195-A1 
O
Cl
OH
O  
 
6/ 12 
 
14/ 23 
 
0.28 
 
 
JPC-2209-A1 
N
OH
Cl
O
O
 
 
 
 
2.5/5.5 
 
 
 
4.6 / 7 
 
 
 
13.8 
 
JPC-2222-A1 
NN
O
O NH
Cl
Cl  
 
 
4.7/7.4 
 
 
3.5/6 
 
 
>50 
 
 
JPC-2310-A1 
N
O
Cl
OH
Cl
 
 
 
 
2.6/4.6 
 
 
 
3.5/6 
 
 
 
>50 
 
JPC-2347-A1 
O
N
H
N
H
O
F3CO CN
 
 
 
0.7/1.4 
 
 
0.8/1.5 
 
 
>50 
 
 
JPC-2365-A1 
O
N
H
N
H
O
Cl
CF3
F3CO
 
 
0.15/0.2 
 
0.14/0.2 
 
>50 
 
 
JPC-2497-A1 NH
O
N
H
NC
F3C
O
Cl
Cl  
 
 
 
0.3/0.7 
 
 
 
0.3/0.6 
 
 
 
>50 
 
 
JPC-2506-A1 NH
O
N
H
O
Cl
Cl
OCF3
ClF3C
Cl
F3C
 
 
 
 
0.04/0.07 
 
 
 
0.07/0.16 
 
 
 
>50 
 
 
JPC-2546-A1 
Cl
F3C NH
O
O
Cl
O
Cl Cl  
 
 
 
0.6/0.8 
 
 
 
0.6/0.7 
 
 
 
>50 
 
JPC-2553-A1 
N
O
Cl
F3C CF3
NH2
 
 
 
48/>50 
 
 
43/>50 
 
 
>50 
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3.3 Discussion 
The results described above represent a significant achievement in understanding 
of the mode of binding of triclosan derivatives to PfENR. Thus, substitutions in positions 
1,5 of ring A and 2’,4’of ring B as well as the linker (ether atom) position gave us a better 
visualization of the capacity to design and obtain new potent drugs which target PfENR 
by modification of triclosan scaffold. 
The triclosan binding site resembles that of bacterial FabI from E. coli and M. 
tuberculosis, explaining why triclosan and structurally related compounds strongly inhibit 
PfENR11. It has being shown that a single point mutation (A217V) confers triclosan 
resistance in E.coli. In addition, Kapoor et al.74 have studied the effect of mutations in the 
binding site of triclosan to PfENR, to characterize the role played by residues like A, N, 
M and F in triclosan binding generating the following mutations: A217V, A217G, 
N218A, N218D, M281A, M281T, F368A and F368I, concluding that the mutation of Ala 
217 to Val result in unacceptable steric contacts between the side chain of Valine and 
triclosan, leading to reduced affinity of triclosan for the enzyme, which is the same effect 
produced by the other mutations. Therefore, to design better inhibitors derived from 
triclosan scaffold resistance mechanisms used for the parasite have to be taken into 
consideration.21,74,76 
 
Antibacterials like diazaborines (thienodiazoborines or benzodiazoborines) 
isoniazid target ENR in E.coli, M. tuberculosis and P. falciparum by forming covalent 
bond between the 2’hydroxyl of the nicotinamide ribose and a boron atom in the drugs to 
generate a tight, non covalently bound bisubstrate analog.93 
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The position of the aromatic bicyclic ring of the diazaborine, indole 
naphthyridones, Genz-8575, Genz-10850 and triclosan above the nicotinamide ring 
forming π-π stacking interactions among others inhibitors resembles the model proposed 
for the binding of the enoyl substrate on the basis of studies in B. napus ENR.94 In the 
seeking for new antimicrobials that target fatty acid biosynthesis, high-throughput 
screening to identify inhibitors of E.coli ENR have led to the finding of 2-(alkylthio)-4,6 
diphenylpyridine-3-carbonitriles “thiopyridines” that were capable of inhibit purified 
ENR and the cells of S. aureus and B. subtilis showing to be effective fatty acid 
biosynthesis inhibitors.95 In addition new metabolites (iridoid glycoside, pyrrolidinium 
derivatives, phenylethanoid glycosides, luteolin 7-O-β-D-glucopyranoside with IC50 
values of 2.4 µg/mL and chrysoeriol 7-O-β-D-glucopyranoside with IC50 value of 5.9 
µg/mL, against the parasite among others metabolites) isolated from Phlomis 
brunneogaleata have been recently tested by Tasademir et al.96 as possible compounds to 
treat malaria which have PfENR as a target, showing for compound luteolin 7-O-β-D-
glucopyranoside an IC50 value of 10 µg/mL, this compound is suggested to be the first 
anti-malarial natural product targeting PfENR.96 
For the triclosan derivatives evaluated in this study replacement of the hydroxyl 
group at position one of triclosan resulted in the finding of new potent inhibitors (urea 
series), as is the case with compound JPC-2201-A1 which resulted in satisfactory 
inhibitory activity against the parasite (20 times more active than triclosan) However, this 
compound did not have any effect on PfENR activity. A similar scenario was found when 
modifications in the linker ether group took place. When complex organic modifications 
were added to the structure at this ether position the inhibitory capacity of the resulted 
 80
analog was affected. Meanwhile, substitutions capable of generating hydrogen bonding as 
is exemplified by the amino in compound JPC-2578-A1 (almost as potent as triclosan), 
are capable of maintaining the interactions at this position stabilizing the binding of these 
analog to PfENR. Moreover, replacement of chloride groups at position 2’ and 4’ with 
groups that have hydrogen bonding characteristics, as is the case of compounds JPC-
2136-A1 (almost 20 times less active than triclosan in both the whole cell and the PfENR 
assay) with an amino group that targets the enzyme, has low potency against the parasite. 
This does not happen with the nitro group of compound JPC-2137-A1 that has shown to 
be very effective (three times less active than triclosan) against both, the enzyme and the 
parasite. On the other hand, for compounds where more complex groups were introduced, 
as in the case of the group of 1H-tetrazol-5-yl compound JPC-2141-A1, it was not 
effective against the parasite (50 times less potent than triclosan) but had a reasonable 
activity (10 times less potent than triclosan) against the PfENR. Another compound 
capable of generating hydrogen bonds at this position was resulted from morpholine-4-
carboxylic acid group, compound JPC-2153-A1 which, in fact, had interactions with 
Ala219 and Asn218 responsible of the hydrogen bond formation at this region of the 
protein. This compound also had moderate activity (30 times less active than triclosan) 
against PfENR and low activity (50 times less potent than triclosan) against the parasite. 
This also occurred with the N-methyl amide of JPC-2166-A1 which had potent 
inhibitory activity (10 folds less potent than triclosan) against the enzyme but moderate 
activity (30 times less effective than triclosan) against the parasite.  
The replacement of the chloride group at position 5 of triclosan for groups 
capable of generating new π-π stacking interaction with Tyr267, Try277 or Phe368 (as 
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was the case for the inhibition in ENRs from other organism, e.i. InhA in mycobacterium 
tuberculosis)97 led to the determination of the binding characteristics for compound JPC-
2305-A1. A tolyl group was placed at this position, improving the activity against the 
parasite as well as the activity against PfENR, which was only five times less than that 
for triclosan. 
The IC50 values obtained in this study allows correlating the potency of triclosan 
analogs as inhibitor of PfENR. However, for those analogs that do not target the enzyme, 
for example most of the urea (substitutions at position one of triclosan) compounds and 
most of the phenylsulphonamides (substitutions at position two) derivatives but are 
potent inhibitor of P.falciparum in the whole cell assay, to answer the questions about 
what is the target of these compound within the parasite define the new challenges in this 
research. Therefore, to investigate in vitro drug interactions of two antimalarials, standard 
dose-response assays over a range of individual drug concentrations are used. Knowing 
this information, a graphical representation of growth inhibition data for two compounds, 
plotted as fractional IC50 values on an X-Y axis (isobologram) permit the determination 
of whether the two compounds are synergistic, additive or antagonistic allowing a more 
clear understanding of the mode of action of these drugs in the parasite.5 
In general, a low percentage of the inhibitors generated in this study had 
considerable inhibitory activity against PfENR. However none of these inhibitors shown 
a better inhibitory activity than triclosan in the enzymatic determination, nevertheless 
several of these inhibitors were very potent against the parasite, leading us to formulate 
some hypothesis about the possible targets of those derivatives within the parasite. 
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There are several studies reporting the mode of action of triclosan in different 
organisms.98,99 Inhibition of fatty acid biosynthesis is the most widely accepted.99 
However, it was originally thought that triclosan acted nonspecifically by disrupting 
cellular membranes99. Therefore, it is likely that the triclosan derivatives evaluated in this 
study have other targets within the intracellular components of the parasite (trophozoite, 
intra-erythrocytic stage of the life cycle). 93,97-100 
Taking into account the remarkable information obtained with the genome 
mapping of P. falciparum, where it was determined 5,268 predicted proteins, of which, 
733 were identified as enzymes, 2/3 of the proteins appear to be unique to this organism 
and, 551 nuclear-encoded proteins may target the apicoplast and or mitochondrion. 
Within these proteins are housekeeping enzymes involved in DNA replication and repair, 
transcription, translation and post-translational modification, cofactor synthesis, protein 
import, protein turnover, and specific metabolic and transport activities. Moreover, it was 
also found that the apicoplast has a 35-kb genome that encodes 30 proteins and in 
addition to fatty acid biosynthesis, other important functions like anabolic synthesis of 
isoprenoids and hemes take place in this organelle.6,101-109 Therefore, with this genetic 
information we can hypothesize about the possible targets that allow an alternative mode 
of action for the triclosan analogs described in this study which, do not have an effective 
enzymatic activity against PfENR, however are very potent whole cell growth inhibitors, 
as is the case of the urea (substitutions at position one of triclosan) compounds and 
phenylsulphonamides (substitutions at position two) derivatives. 
For the in vivo determination of the potency of triclosan derivatives described in 
this study we used the erythrocytic (trophozoite) stage of the parasite. Therefore, from the 
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metabolism point of view, erythrocytic P falciparum relies principally on anaerobic 
glycolysis for energy production, with regeneration of NAD+ by conversion of pyruvate 
to lactate.6,110,111. It is known that genes encoding all of the enzymes necessary for a 
functional glycolytic pathway (PFK, pentose phosphates pathway, but not fructose 
bisphosphatase) are present in P. falciparum, as well as the genes necessary for a 
complete TCA cycle, including a complete pyruvate dehydrogenase complex (likely to be 
localized in the apicoplast). In addition to genes encoding all subunits of the catalytic F1 
portion of ATP synthase, and the gene that encodes the proteolipid subunit c for the F0 
portion of ATP synthase. It is also known that chorismate is made from erythrose 4-
phosphate and phosphoenolpyruvate via the shikimate pathway and that all the life cycle 
stages of the parasite are incapable of the de novo purine synthesis. 6,112-119  
Considering the facts quoted above, it is reasonable to suggest these important 
metabolic pathways as possible targets for the action of the triclosan derivatives 
evaluated in this study which are potent inhibitors of P. falciparum. 
We can also consider the transport system within the parasite as a possible target 
for these inhibitors. The presence of an elaborate membrane transporter system are 
lacking in P falciparum genome, particularly, for uptake of organic nutrients, there are 
low percentage of multispanning membrane proteins, and no amino acid transporter, 
emphasizing the importance of hemoglobin digestion within the food vacuole as an 
important source of amino acids for the erythrocytic stages of the parasite, where it is also 
found transporters for the mobilization of inorganic ions, export of drugs and 
hydrophobic compounds6,112,120. Moreover sodium/proton, calcium/proton exchangers as 
well as other metal cation transporters were identified. The parasite contains all subunits 
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of V-type ATPase as well as two proton translocating pyrophosphatases, which could be 
used to generate a proton motive force, possibly across the parasite plasma membrane as 
well as across a vacuolar membrane.6,119,120 The proton pumping pyrophosphatases are 
not present in mammals, and could form an attractive antimalarial targets. 6 
Dealing with DNA replication, repair and recombination, taking into account the 
genomic information it is known that the core of eukaryotic nucleotide excision repair is 
present in P. falciparum, although others proteins could not be found, being the same 
case for proteins involve in the homologous recombination and repair.6,120 However, 
there are no known inhibitors of this system in malaria. Therefore, this will be a possible 
target to study in the search for the mode of action of these triclosan analogs. 
For the secretory pathways the parasite contains genes encoding proteins that are 
important in protein transport in other eukaryotic organisms, there are homologs of 
important components of the signal recognition particle, the translocon, the signal 
peptidase complex and many components that allow vesicle assembly, docking and 
fusion, making this system another reasonable target to consider for the action of these 
inhibitors.6,120,121 
In connection with fatty acid biosynthesis, it is known that the surface of 
bloodstream stage of apicomplexan parasites (Trypanosome brucei and P. falciparum) 
contains the glycosyl phosphatisylinositol (GPI) anchor of the parasite variant surface 
glycoprotein (VSG) that enshrouds the cell surface of the parasite, protecting it from 
destruction by the host immune system.92,121,122 This GPI is unusual in that its fatty acyl 
moiety is exclusively myristate, a 14-carbon saturated fatty acid that is efficiently 
salvages and processes myristate from the blood stream, but it also makes myristate de 
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novo using a reaction pathway known as fatty acid remodeling, where myristate is post-
synthetically incorporated into the GPI precursor.92,113-115,122 Paul et al96. Studying 
Trypanosome brucei found that triclosan inhibited multiple steps of the in vitro fatty acid 
remodeling pathway in the same concentration range required to kill Trypanosome brucei 
in culture, also similar concentration of triclosan inhibited myristate exchange, a second 
biochemically distinct myristoylation pathway. However, it is likely that the fatty acid 
remodeling and myristate exchange pathways are being nonspecifically inhibited by 
triclosan perhaps, by perturbation of the membrane structure, it also have been shown 
that triclosan, being very hydrophobic, was incorporated into bacterial and eukaryotic 
membranes producing a subtle alteration of the physicochemical properties of artificial 
lipids bilayers and liposomes. It is suggested that in T. brucei, triclosan acts upon cellular 
membranes, perturbing their physical properties and thereby disrupting the function of 
some membrane resident enzymes.93,97,100,122 
Considering the finding of the mode of action of triclosan in T. brucei, we can 
hypothesize the possibility that some of the triclosan derivatives evaluated in this study 
can have the same mode of action in the in vivo evaluation of P falciparum.123 
Another situation faced by antimicrobials and other small molecules to 
sequestered parasites is the transporting of the inhibitors within the cell which could 
affect the inhibitory potency of the drug due to its limitation to reach de desire target, one 
method to avoid this situation for triclosan delivery in Toxoplasma gondii (tachyzoites) 
was to use triclosan conjugated to arginine oligomers. Triclosan released after 
conjugation to octaarginine via a readily hydrolysable ester linkage inhibits ENR activity, 
tachyzoites in vitro, and tachyzoites in mice. If this is the case for the inhibitors in this 
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study, one future challenge to face in continuing exploring triclosan analogs will be their 
delivery into the microorganism (P. falciparum). Therefore, to use oligomers of arginine 
will become a suitable alternative to overcome this problem and ensure that the drug gets 
into the parasite to further explore and understand its mechanism of action.120-124 
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CHAPTER IV 
CONCLUSIONS AND FUTURE WORK 
 
 
 
Diseases produced by microorganism have been a health problem in every society 
around the world since ancient times. Infections like malaria, tuberculosis, leishmania, 
and Chagas disease, among others transmitted by microorganisms, are responsible for 
millions of deaths annually mainly in developing nations. Therefore, there is an urgent 
need for the development of antimicrobial agents that are inexpensive and capable of 
controlling the disease without being harmful to humans. Considering the fact that 
metabolic pathways like fatty acid biosynthesis are different in these microorganisms 
compared to mammalian cells we used a known bacterial and apicomplexan fatty acid 
synthase inhibitor, triclosan, as a scaffold to generate analogs of this molecule. Triclosan 
is a compound that has some of the characteristics quoted above, however due to its 
bioliability its use in humans as an antimalarial drug is not yet suitable. Therefore, the 
data presented in this study provides significant information about the structural 
characteristics and properties of the interactions for several types of triclosan analogs in 
the search for new antimalarial drugs that target PfENR. Almost 5% of the 520 inhibitors 
evaluated targeted PfENR, and we were able to establish structural information on the 
mode of binding for six of those inhibitors.  
The information obtained from the crystallographic structures of the analogs gives 
remarkable information about the type of substituent that can be placed in different 
positions in ring A and B of triclosan to improve the binding capacity of the resulting 
analog to PfENR. The correlation on the data obtained for some of the analogs for the in 
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vivo (anti parasite) and the in vitro (anti PfENR) activity allow us to confirm the 
inhibition of fatty acid biosynthesis.  
The SAR study of these triclosan analogs proved to be an effective strategy to 
narrow down the effective search for development of antimalarial drugs that specifically 
target fatty acid biosynthesis. Moreover, the finding of the urea and phenylsulphonamides 
compounds, which are very potent inhibitors of the erythrocytic (trophozoite) stage of the 
parasite but do not target PfENR, create a new challenge for the improvement of their 
inhibitory activity in addition to the determination of the mode of action of these 
inhibitors in P. falciparum. 
The triclosan derivatives obtained from modifications in position 5 of ring A and 
4’ of ring B offers significant information about the kind of modification that can be 
tolerated for this region in the binding side of PfENR, opening up the possibility of 
generating new chimera compounds by combination of effective substituenst at these 
positions in the triclosan scaffold. 
There is still a long way to go in the fight against malaria and others diseases 
produced by microorganisms. However, with the establishment of the genome map of 
these organisms and structural biology studies we can ensure the discovery of a drug 
capable of controlling this disease will soon be a reality. 
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Future work in the research of PfENR inhibitors as a strategy to control malaria 
include the evaluation of the activity of different chemical libraries of compounds to 
ensure a diversity of possible chemical structures that could bind to PfENR. laboratory 
here at Texas A&M as well as pharmaceutical companies like GlaxoSmithKline are 
currently undergoing projects to the screen 500.000 compounds against PfENR21. In 
addition malaria produced by Plasmodium vivax is also a threat responsible for many 
deaths around the world. Therefore, evaluation of the triclosan derivatives obtained in 
this study as well as structural studies of the Plasmodium vivax ENR (PvENR) will be a 
major priority to better understand the effects of these compounds in other plasmodium 
species. 
In this study we obtained six crystallographic structures of PfENR-NAD+-
triclosan analogs. However, there are many more of these analogs from which we could 
get X-ray structures to better understand their mode of binding to PfENR. Therefore, one 
priority in continuing this research will be to obtain crystal structures of derivatives 
where substitutions at position 5 and 6 of ring A as well as position 4’ of ring B were 
made, to continue gaining more information about the interactions taking place in the 
PfENR active side with different triclosan analogs. 
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